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ABSTRACT 
The goal of this thesis was to develop, construct, and validate the Perceived Economic 
Burden scale to quantitatively measure the burden associated with a subtype 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) in families from the island 
of Newfoundland. An original 76 item self-administered survey was designed using 
content from existing literature as well as themes from qualitative research conducted by 
our team and distributed to individuals of families known to be at risk for the disease. A 
response rate of 37.2% (n = 64) was achieved between December 2013 and May 2014. 
Tests for data quality, Likert scale assumptions and scale reliability were conducted and 
provided preliminary evidence of the psychometric properties of the final constructed 
perceived economic burden of ARVC scale comprising 62 items in five sections. 
Findings indicated that being an affected male was a significant predictor of increased 
perceived economic burden in the majority of economic burden measures. Affected males 
also reported an increased likelihood of going on disability and difficulty obtaining 
insurance. Affected females also had an increased perceived financial burden. Preliminary 
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Chapter 1: Introduction 
Stories like that of Rick Ralph highlighted in Memorial University of 
Newfoundland’s ‘Dare To’ campaign are not uncommon in the province of 
Newfoundland and Labrador, where a lethal genetic cardiac condition affects many 
families. The short video link provided in the footnote presents the story of Rick Ralph, 
an Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) patient for whom 
research like that conducted in this study has made a significant impact both for him, and 
his young family.1 It is for families like the Ralphs that ongoing research continues in the 
hopes of making positive contributions to the holistic management of this life threatening 
disease. This study focuses on exploring the perceived economic burden of ARVC caused 
by a p.S358L mutation in TMEM43, to further understand its psychosocial effect on 
families, inform the provision of health services and contribute to the wider literature on 
the economic burden of genetic disease.  
1.1 Problem Statement 
ARVC has been affecting families since the 18th century when the Pope’s 
physician Giovanni Maria Lancisi first documented it in his book De Motu Cardis et 
Aneurysmatubus (Romero, Mejia-Lopez, Manrique & Lucariello, 2013). Since then, 
significant research has been undertaken on ARVC that has resulted in an increased 
understanding of the cause, manifestation and treatment of the disease. ARVC is a 
genetically determined heritable heart disease causing irregular heart rhythms 
(arrhythmias), potential heart failure and sudden cardiac death (SCD).  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 https://www.youtube.com/watch?v=bOwemOKYFIQ 
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On the island of Newfoundland, Canada, a particularly lethal subtype of ARVC is 
prevalent caused by a p.S358L gene mutation in TMEM43 (Merner et al., 2008). A small 
but significant population of 25 families are known to be genetically at risk for the 
disease, comprising approximately 900 individuals past and present born at 50% risk of 
inheriting the genetic mutation (Hodgkinson et al., 2013). Advancements in genetic 
testing have hastened the identification, management and clinical monitoring of this 
population, along with the creation of a local ARVC registry used for both clinical and 
research purposes. Early identification of affected individuals allows for appropriate 
treatment decisions, often the implantation of a cardioverter-defibrillator (ICD) that 
shocks the heart in response to arrhythmias. Unlike more common cardiovascular 
diseases that manifest later in life, ARVC develops in young-mid adulthood and persists 
over a lifetime. Symptoms of the disease vary greatly between individuals and sexes, 
where men tend to develop more severe symptoms beginning at an earlier age. The most 
notable of symptoms is SCD, which most often occurs in seemingly young and otherwise 
healthy individuals.  
 An identified gap within existing psychosocial literature exists on the perceived 
economic burden of inherited illness, including the inherited cardiac condition of ARVC. 
This study is a contribution to a larger investigation into the genetics-related, ethical, 
environmental, economic, legal and social (GE3LS) aspects of ARVC. It focuses on 
providing descriptive measures at the microeconomic level, that is, the level of the 
household, family and individual (Ruger et al., 2006). To date, the majority of economic 
studies focus on the macroeconomic or societal level, which does not provide evidence on 
how individuals and families themselves perceive the economic burden of ARVC.  
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What is known, however, is that chronic disease can have a significant economic 
impact on individuals and their families. Reports also indicate that economic hardship in 
diseases such as cancer can contribute to a lower quality of life (Meneses et al., 2012). 
Furthermore, costs incurred by the acquisition of health goods and services as a 
consequence of disease can significantly impact the ability of individuals and their 
families to purchase and consume other goods and services (World Health Organization 
[WHO], 2009).  
A possible lifetime of symptoms associated with ARVC and a risk for premature 
and possible sudden death can alter various economic outcomes of at risk individuals and 
families. For example, decisions pertaining to education, careers, and finances all have 
the potential to be affected by a risk for ARVC. Moreover, costs associated with the 
disease both directly and indirectly can result in financial burdens for families. Finally, 
the ability to acquire insurance to reduce the financial burdens that health costs place on 
families or to ensure financial security in the future may also be affected.  
Even though many direct medical costs are covered by the publicly funded health 
care system in Canada, only 70% of direct medical costs are funded through 
provincial/territorial health insurance (Paris et al., 2010). Travel, accommodation, and 
medication costs are all costs exempt from the publicly funded health care system and as 
a result, are absorbed either by additional private medical insurance or by families 
themselves. The clinical management of ARVC patients in Newfoundland occurs at the 
Cardiac Genetics clinic at the Health Sciences Centre in St. John’s (the tertiary referral 
centre for the Province of Newfoundland and Labrador) requiring many patients to travel 
from other parts of the province for their care. Additionally, some patients are required to 
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travel out of province for some aspects of care and incur costs for travel and 
accommodation, as well as lost time at work. 
1.2 Research Question and Objectives 
The purpose of this cross-sectional descriptive study was to develop, pilot and 
conduct preliminary evaluation of an instrument to measure the perceived economic 
burden associated with being born at risk of ARVC caused by a p.S358L mutation in 
TMEM43. It extended to explore the possible trends between ARVC and measures of 
economic burden identified in the literature from the perspective of the individual, 
household and family. 
The study objectives were: 
1. To develop and pilot a survey instrument using existing ARVC and other 
relevant literature to collect data on the perceived economic burden of ARVC.  
2. To construct and provide preliminary validation of the Perceived Economic 
Burden (PEB) scale. 
3. To conduct empirical analysis using the PEB scale to identify predictors of 
perceived economic burden of ARVC, particularly sex and clinical status.2 
1.3 Rationale 
 Few health economic studies reported in the literature focus on the 
microeconomic environment since measuring an impact at the societal or macroeconomic 
level are considered of greater importance, particularly in high-income countries. Jeon et 
al. (2009) suggest that the economic consequences on patients and households are often 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  Previous clinical studies indicate that sex and clinical status are significant factors in ARVC disease 
progression and severity (see: Hodgkinson et al., 2013; Merner et al., 2008). As a result, these indicators are 
afforded a specific focus in addition to other possible predictors as identified through the data analysis.	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overlooked in high-income countries with publically funded health care systems, a 
possible explanation for the minimal number of microeconomic studies in countries such 
as Canada. Nevertheless, reports suggest that despite a publicly-funded health care 
system, health-related costs to families are increasing in Canada (Sanmartin et al., 2014). 
Increased costs for health-related expenses cause economic burden in chronic disease 
populations and often lead to households facing difficult decisions between care and basic 
living expenses (Jeon et al., 2009).  
Research is lacking on the economic burden of ARVC, with only a single 
qualitative study conducted by Etchegary et al. (2015). The lack of literature extends to 
other inherited and non-inherited heart diseases, and many genetic conditions in general. 
As such a gap in the wider literature has been identified. This study represents the first 
quantitative investigation of its kind not only within Canada but also internationally. In 
the absence of knowledge concerning how ARVC affects the economic decisions of 
individuals and families, limits on the optimal holistic approach to care exist. An 
understanding of the experienced economic burden from disease on families is necessary 
to inform and guide optimal patient care and future policy development.   
 Findings from this study will provide an understanding of the effect that a risk for 
ARVC has on various economic measures of burden for individuals and families. This 
knowledge can aid clinicians in providing the most comprehensive, holistic management 
and guidance for ARVC patients. This knowledge may also inform policy decisions 
related to programs and services provided to ARVC patients and other similar populations 
facing economic burden as a result of disease. Finally, results can be used to inform 
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further research on the economic challenges faced by ARVC families and other heritable 
conditions. 
This thesis presents a literature review that provides an overview of ARVC, 
background on the study population, and summarizes what is currently reflected in the 
literature concerning the measures of economic burden. The methodology used to address 
the study objectives is described in the context of the development and construct of a data 
collection survey instrument, the validation of the PEB scale, and both regression and chi-
squared data analysis. Study results are presented and discussed as they reflect the 
findings in consideration of this population and existing literature. Finally, the 
conclusions of the study are presented including recommendations for future research on 
this population and relatable conditions.  
 This thesis comprises the economic component of the GE3LS research. All phases 
of this research were planned and executed by the author (Glenn Enright) with advice 
from the academic supervisory committee responsible for GE3LS. The supervisory 
members consist of a genetic counselor, a health economist, a clinical research scientist, 
and a medical ethicist. The committee is sometimes referred to as the research team in 
this thesis. At various stages of the research, advice and recommendations were sought 
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Chapter 2: Background & Literature Review 
2.0 Literature Review  
A lack of research is evident in the literature pertaining to the economic burden 
experienced by ARVC patients and their families. The purpose of this research is to 
address this issue. Possible explanations for the absence of literature in this area are 
discussed in detail in the proceeding sections; however, they can be summarized briefly, 
and include (a) the relatively small ARVC population, (b) the research focus on the 
clinical management of the disease, and (c) the preference for economic studies at the 
societal or macroeconomic level. This literature review will reveal the lack of economic 
burden studies on ARVC patients and families, while discussing economic studies on 
related conditions, providing sufficient evidence and background information to 
rationalize the importance of conducting this study. 
This literature review comprises two major sections. Firstly it addresses 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) presenting an overview of 
the biological, genetic, and medical understanding of the disease. Furthermore, ARVC as 
it occurs in the Newfoundland population, is also explained including disease 
characteristics of the specific genetic subtype of ARVC targeted in this study. It is 
essential to appreciate the various characteristics of this disease in order to understand 
how the disease can lead to a perceived economic burden for patients and their families.  
The second section presents the measures of economic burden used in this study 
and explores how illness and disease (particularly a chronic disease such as ARVC) 
causes economic burden to patients and their families. A single qualitative study 
conducted by members of this research team exists that explores the economic burden of 
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ARVC, discussed in detail in section 2.2. To date, no quantitative studies exist on the 
economic burden of ARVC or other genetic cardiomyopathies. The relatively few 
microeconomic studies that exist in the wider literature on similar conditions to ARVC 
such as heart diseases and other genetic diseases as well as chronic illness and disease are 
reviewed in section 2.3. Finally, a brief summary of this chapter is included in section 2.4. 
2.1 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
 ARVC is classified as a genetically determined primary myocardial disease in 
which the heart muscle is structurally and functionally abnormal (Elliot & Mohiddin, 
2012). Structurally, it is characterized by the progressive replacement of normal 
myocardial (heart muscle) tissue with fibrous and adipose (fat) tissues mostly within the 
right ventricle, although left ventricle tissue changes are also reported (Azaouagh et al., 
2011; Campuzano et al., 2012; Romero et al., 2013). It is thought that fibro-fatty 
replacement of muscle interferes with the connections between the muscle cells 
disrupting the electronic signaling pathways responsible for heart contractions (Basso et 
al., 2009). Disruption of the electronic impulses leads to functional abnormalities in the 
form of irregular heartbeats, resulting in arrhythmias, heart failure and possible SCD 
(Basso et al., 2009; Cahill et al., 2013). Prognosis for patients is highly dependent on 
factors such as the genetic subtype of ARVC, the rate of disease progression, availability 
of treatment and follow-up and often sex, as males are often affected more severely than 
females.  
 ARVC is estimated to affect between 1 in 2000-5000 people within the general 
population, although some researchers suggest that difficulties with diagnosis may cause 
under representation and the true rate could be as high as 1 in 1000 (Corrado et al., 2000; 
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Murray, 2012; Sen-Chowdhry et al., 2010). This disease affects a relatively small 
proportion of the Canadian population, however, it is known that a significant ARVC 
population reside in or have genetic ties to specific families and communities in 
Newfoundland.  
Specifically, one genetic subtype of ARVC commonly found in Newfoundland is 
caused by a p.S358L missense mutation in the TMEM43 gene found on the ARVD5 
region (locus) of chromosome 3 (Merner et al., 2008). While studies are ongoing to 
identify the extent and prevalence of the at-risk population in Newfoundland, the 
prevalence of ARVC caused by this genetic subtype remains unknown, although 
anecdotally is likely to be at least 1/1000 (Hodgkinson, Personal communication, 2014). 
Despite the unknown prevalence, to date, researchers and clinicians have identified 
twenty-five pedigrees with origins to Newfoundland known to carry the ARVC causing 
p.S358L mutation, comprising approximately 900 individuals3.   
2.1.1 Genetics and ARVC 
 ARVC is understood to be a genetic disease. Genes are the basic chemical unit of 
heredity and can be thought of as code sequences that carry information from one 
generation to the next. A change in the normal gene sequence that has obvious phenotypic 
(observable characteristic) effects is known as a mutation, whereas changes within gene 
sequences with no relevant phenotypic effects are known as polymorphisms. Gene 
mutations like those causing ARVC can be inherited from generation to generation 
usually resulting from one of two common inheritance patterns; (i), autosomal dominant 
(AD); and (ii) autosomal recessive (AR). In cases of AD inheritance, there is a 50% 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Dead or living. Since the early 1800’s, identified born at 50% risk of having the TMEM43 gene mutation. 
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chance a child will inherit a gene mutation and its associated characteristic, such as a 
disease or trait, from a parent who possesses the mutation. In cases of AR inheritance, the 
chance of inheriting a mutation remains 50%; however, the chance of developing the 
disease/trait is reduced to 25% as both parents must possess and pass on the gene 
mutation.  
 ARVC is most commonly associated with an AD inheritance pattern (Basso et al., 
2009). Thus far, twelve subtypes of autosomal dominant ARVC have been identified 
named ARVD1 through ARVD12 respectively, based on the genetic location of the 
mutation (Romero et al., 2013). A single autosomal recessive AR subtype of ARVC 
exists and is referred to as Naxos Disease. Although many commonalities exist between 
ARVC types, differences in disease progression and severity of symptoms are observed 
between genetic subtypes (Romero et al., 2013). 
Both family history and genetic testing provide insight into the genetic 
characteristic of ARVC. Research demonstrates that a family history of ARVC or SCD is 
found in approximately 20%-30% of cases (Marcus et al., 2013). This is most likely a 
somewhat conservative estimate however, as within a cardiac setting, family history is 
often overlooked, rarely documented or never asked. (Hodgkinson, personal 
communication, 2014; Marcus et al., 1982). Similar to family history, an underestimate of 
the proportion of genetic-related ARVC is probable on the assumption that undiscovered 
disease-causing gene mutations exist. ARVC disease-causing gene mutations are present 
in 50% of patients with ARVC who present to cardiac clinics, evidence that undiscovered 
disease-causing genes remain (Marcus et al., 2013).  
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2.1.2 Symptoms of ARVC 
Patients with ARVC can experience a wide range of symptoms with varying 
severity. Initial symptoms of the disease most commonly appear between 15 and 35 years 
of age, with first symptoms rarely arising in early childhood or beyond 60 years of age 
(Wichter et al., 2005). Most commonly, symptoms of ARVC include palpitations 
(irregular heartbeats perceived by patients), pre-syncope (dizziness), syncope (fainting), 
and chest pain (Hamilton, 2009). Heart failure develops in about 10%-20% of ARVC 
patients when the heart is no longer functional enough to adequately circulate blood 
(Cahill et al., 2013; Heart and Stroke Foundation, 2013b).  
The most devastating and often the first and only symptom of ARVC is SCD. 
Research suggests that approximately 20% of all sudden deaths are attributable to ARVC, 
occurring most frequently in young adults and athletes (Murray, 2012; Romero et al., 
2013). Corrado et al. (2003) conclude that ARVC patients who engage in sport or 
vigorous physical activity are at a five times greater risk for SCD. An increased risk of 
SCD occurs with vigorous activity resulting from the significant physical stress and 
increased stimulation of the heart muscles that increase the likelihood for arrhythmias 
(Basso et al., 2009; Wichter et al., 2005). Such physical activities may also further disease 
progression as a result of stress induced on the heart (Corrado et al., 2003). Even though 
physical activity increases the risk for SCD, this does not suggest that SCD cannot occur 
in the absence of physical activity. A study of 200 ARVC-associated SCDs by Tabib et 
al. (2003) concluded that death most frequently occurs during sedentary activity.  
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2.1.3 Diagnosis of ARVC 
Diagnosis of ARVC in patients can be difficult due to fluidity in the progression 
of the disease over time. Hypothetically, initial symptoms may be indicative of a 
relatively mild heart condition; however, as the disease progresses, the disease may look 
like other heart conditions (e.g., with left ventricular involvement ARVC can mimic 
dilated cardiomyopathy) and may not be diagnosed as ARVC (Pirzada et al., 2015). 
Difficulties with diagnosis led to a consensus by experts on proposed criteria referred to 
as Task Force Criteria for ARVC (McKenna et al., 1994). The 1994 criteria combined 
abnormalities in heart structure, pathology, electrical impulses rhythms and family history 
to establish diagnosis. Each criterion was categorized into major or minor sub 
classifications based on their known association with ARVC. A diagnosis of ARVC was 
based on combinations of the number of major and minor criteria for each patient; two 
major, one major plus two minor or four minor criteria were required for diagnosis.  
In an effort to increase sensitivity of the diagnostic criteria, Marcus et al. (2010) 
subsequently updated the preceding 1994 Task Force criteria. The updates consider 
changes in clinical understanding, advancement in diagnostic technologies and most 
notably, newly available genetic mutation testing for ARVC. Marcus et al. (2010) also 
updated the requirements for diagnosis to include three main diagnostic levels; a definite 
diagnosis: two major or one major and two minor criteria or four minor from different 
categories; borderline diagnosis: one major and one minor or three minor criteria from 
different categories and; possible diagnosis: one major or two minor criteria from 
different categories. Both original 1994 and updated task force criteria are presented in 
Appendix A.  
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Presently, a variety of diagnostic tools are used to assess diagnostic criteria in at 
risk individuals along with monitoring disease progression in diagnosed ARVC patients. 
Common tests include electrocardiographs (ECGs), Holter monitors, echocardiograms, 
magnetic resonance images (MRIs), cardiac biopsies and genetic mutation analyses. 
Although task force criteria continue to be the ‘gold standard’ in ARVC diagnosis, 
Hodgkinson et al. (2013)  note that these descriptive diagnostic characteristics prove 
difficult for the ARVC population in Newfoundland, particularly in areas that lack 
tertiary testing, and therefore continue to lack sensitivity. Hodgkinson et al. (2013) argue 
that the descriptive criteria presented by Marcus et al. (2010) would not efficiently 
diagnose ARVC in the Newfoundland population as many patients present with death in 
rural areas, often where availability of clinical testing is scarce (Hodgkinson et al. 2013). 
In these circumstances, Newfoundland subjects would not meet the descriptive criteria 
required for diagnosis. Furthermore, the necessary diagnostic equipment to test for task 
force criteria are not available in Newfoundland (Hodgkinson, personal communication, 
2014). Historically, diagnosis in this population has proven difficult prior to the advent of 
genetic testing and the discovery of the TMEM43 p.S358L mutation. 
 In order to utilize the wealth of information from family histories (for example, 
the presence of early sudden death), a unique set of diagnostic and epidemiological 
criteria for ARVC in Newfoundland families was created that relies heavily on family 
history and genetic mutation analysis (Hodgkinson et al., 2013). The criteria identify 
three separate groups of clinical status; (i) Affected; (ii) Unaffected; and (iii) Unknown. 
Criteria for these diagnostic groups are presented in Table 2.1. 
 
	   14 
Table 2.1 Clinical and epidemiological diagnostic criteria for ARVC caused by a p.S358L 
mutation in TMEM43 in the Newfoundland population 
Clinical Status Criteria 
Affected 
- One of the following: 
• Obligate Carrier 
• SCD under 50 years of age 
• Cardioversion for VT or VF under 50 
years 
• Genetic Diagnosis: gene mutation 
(TMEM43 p.S358L) positive 
Unaffected • Gene mutation (TMEM43, pS358L) negative. 
Unknown 
• Do not fulfill criteria for affected or 
unaffected (e.g., no gene mutation 
screening) 
 
2.1.4 ARVC in Newfoundland Families 
Some genetic diseases are common in Newfoundland because of the way the 
province was settled. The current population was derived from a small number of settlers 
who formed large families that were usually geographically isolated and had limited 
immigration and migration. This provides the basis for a founder effect: the reduction in 
genetic variability occurring when a population is derived from a small number of 
colonizing ancestors (Teare, 2011). This effect is evident in the ARVC population in 
Newfoundland caused by TMEM43 p.S358L where all 25 families are known to be 
genetically linked to a pair (founders) who settled in Newfoundland in 1799 (Hodgkinson 
et al., 2013).  
ARVC was first identified in the Newfoundland population in the 1980s when a 
patient presented with a known family history of sudden cardiac death (Guiraudon et al., 
1983, case #1). An ongoing search has led to the identification of an additional 24 
families. One family pedigree alone (family 64) contains over 1200 individuals spanning 
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10 generations. The genetic investigation into the disease in the province evolved in 1998 
when advancements in genetic testing allowed an American research team to link ARVC 
in Newfoundland families to chromosome 3p25 (Ahmad et al., 1998). Local genetic 
research on ARVC began in 1997 at Memorial University of Newfoundland, resulting in 
the discovery of a novel ARVC disease causing p.S358L mutation in TMEM43 by Merner 
and colleagues in 2008.  
2.1.5 ARVC caused by p.S358L in TMEM43 
 Studies have shown that this genetic subtype is a severe and particularly lethal 
autosomal dominant (AD) form of ARVC originally described in Newfoundland families, 
with more recent identification in families from Denmark, Germany and the United States  
(Milting et al., 2014). Recall that AD inheritance patterns exhibit a 50% risk of inheriting 
a genetic mutation from a parent, thus children born to an affected parent have a 50% risk 
of inheriting the disease causing gene and consequently the disease. Therefore all affected 
individuals must have been born at a 50% risk, and subsequently all persons born to an 
affected person had to be born at 50% risk. The term used to describe this population 
from a risk perspective is a priori 50% risk (what risk were you born with?). Even though 
individuals are born a priori 50% risk, their risk status changes as per diagnostic criteria 
established by Hodgkinson et al. (2013) and outlined in table 2.1. Unaffected individuals 
thus have a risk reduction to 0%, and those affected have a risk status of 1.4  
Disease progression and disease severity vary greatly between genetic subtypes of 
ARVC. The disease causing p.S358L mutation in TMEM43 subtype of ARVC is highly 
sex-influenced where men experience earlier onset of symptoms, increased disease 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4Individuals with unknown status remain at 50% risk.    
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severity and shorter life expectancies (Hodgkinson et al., 2013). A representation of the 
influence of sex is demonstrated in the findings of Merner et al. (2008) who found the 
median age at which affected individuals exhibit signs of the disease is 32 years for males 
and 44 years for females.  
In addition to observed differences between males and females, another 
characteristic of ARVC caused by p.S358L in TMEM43 is the disease reaches 100% 
penetrance in affected individuals. This suggests that all individuals with an affected 
status will develop symptoms of the disease in their lifetime, assuming they live a normal 
lifespan (or experience premature death resulting from SCD) (Merner et al., 2008). Full 
penetrance occurs by a median age for males and females at 63 and 76, respectively 
(Merner et al., 2008). This study also reports a reduced life expectancy in the population; 
median life expectancy of 41 years for affected males and 71 years for affected females 
compared to 83 years for both unaffected sexes.  
It is therefore evident that the ARVC caused by a p.S358L mutation in TMEM43 
described in Newfoundland families is severe, sex-influenced and causes premature death 
in both males and females. The TMEM43 ARVC population in Newfoundland has 
important significance for research as the heterogeneity of disease characteristics for 
ARVC caused by other identified mutations makes understanding different aspects of the 
disease difficult, whereas the TMEM43 population allows for accurate, robust information 
for a homogenous disease population.  
2.1.6 Clinical Management of ARVC 
 Individuals at risk for ARVC and those who have developed the disease are 
subject to a lifetime of clinical monitoring, disease management and treatment to slow 
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disease progression and prevent serious events, namely SCD (Basso et al., 2009). ARVC 
treatment is highly individualized given that some patients remain asymptomatic whereas 
major variations in symptoms are observed between patients. As a result, treatment is 
based on clinical presentation, risk assessments for SCD and the preferences of patients 
and physicians.  
Regular cardiac monitoring such as ECGs, Holter monitors and echocardiography 
are used to identify disease progression which is normally sufficient for asymptomatic 
patients and healthy affected gene carriers, who do not require immediate treatment 
(Basso et al., 2009; Wichter et al., 2005). Symptomatic patients, however, are subject to 
various treatment and management strategies including modifications of physical 
activities, pharmacological and non-pharmacological interventions, and surgery. 
Modifications to physical activities act to reduce the risk for exercise-induced 
arrhythmias and SCD. Avoidance or restriction of vigorous physical activity such as 
competitive sports, regular training, and strenuous exertion involving abrupt physical 
effort are usually recommended for high risk and previously diagnosed ARVC patients 
(Basso, 2009; Romero et al., 2013; Smith, 2011).  
Likewise, the use of pharmacological and non-pharmacological interventions to 
reduce cardiac arrhythmias is common in ARVC management. Drugs such as beta-
adrenergic blocking agents (also known as β-Blockers) and the use of antiarrhythmic 
drugs are often prescribed to reduce the frequency of potentially lethal arrhythmias. β-
blockers act to suppress stimulation of the heart muscle from the nervous system reducing 
the heart rate and workload experienced by the heart (Heart and Stroke Foundation of 
Canada, 2011b). Antiarrhythmic drugs such as amiodarone, sotalol and verapamil slow 
	   18 
the electrical impulses that occur within the heart in an effort to maintain regular heart 
rhythms (Heart and Stroke Foundation of Canada, 2011a). Commonly, a combination of 
β-blockers and antiarrhythmic drugs are used either alone or with other non-
pharmacological interventions (Romero et al., 2013). Many of the pharmacological 
treatments for ARVC cause severe side effects, sometimes disrupting the daily lives of 
patients. 
The most widely accepted non-pharmacological treatment for the prevention of 
SCD in ARVC patients is the ICD (Romero et al., 2013). ICDs are implanted to 
normalize irregular heartbeats by monitoring heart rhythms and generating electrical 
shocks when necessary to restore a normal heart rate and rhythm (Heart and Stroke 
Foundation, 2013a). ICD implantation is used for both primary and secondary prevention 
of SCD in ARVC patients (Wichter et al., 2005). Primary prevention includes the 
implantation of an ICD purely for prophylaxis in a patient who is at a high risk for SCD 
(such as affected gene carriers) but shows no evidence of arrhythmias (Hodgkinson et al., 
2005; Romero et al., 2013). Secondary ICD prevention occurs in patients with known 
arrhythmias or who have experienced an aborted cardiac arrest.  
Primary ICD prevention is used for ARVC patients in Newfoundland at high risk 
for SCD based on their genetic testing result (Hodgkinson et al., 2005). A number of 
studies support that ICD therapy improves long-term survival of high risk ARVC patients 
by terminating lethal arrhythmias (Basso et al., 2009; Hodgkinson et al., 2005; Romero et 
al., 2013; Wichter et al., 2005). This is particularly evident in the TMEM43 population 
where ICD implantation is known to significantly improve survival chances (Hodgkinson 
et al., 2005). It is also important, however, to recognize that ICD implantation is not 
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without risk. For example, incidents of inappropriate shocks have been reported and as 
such, the decision to pursue ICD therapy is highly complex. 
Many of the previous surgical treatment approaches for ARVC have been 
replaced by treatment using ICD implantation (Romero et al., 2013). In some cases, a 
heart transplant becomes the final treatment option for patients who develop severe heart 
failure or severe recurrent arrhythmias that do not respond to conventional treatment 
(Calkins & Marcus, 2008). A heart transplant consists of the surgical removal of the 
diseased heart and its replacement with a donor heart (Heart and Stroke Foundation, 
2012). Calkins and Marcus (2008) suggest that few ARVC patients require heart 
transplant as a treatment for their disease. 
For ARVC patients in Newfoundland, all diagnostic procedures including genetic 
testing and in many cases, treatment and clinical monitoring, occur at the Cardiac 
Genetics Clinic at the Health Sciences Centre in the City of St. John’s. Genetic testing for 
this population can occur as early as 10 years of age; however, the decision relies heavily 
on the preferences of the family and the maturity level of the minor. Patients with ICDs 
receive consistent follow up every six months to one year, whereas those that that do not 
require ICD intervention are monitored on a bi-annual basis. Diagnosis and treatment 
strategies for ARVC patients in Newfoundland are highly interdisciplinary and include 
researchers, cardiologists, psychologists and genetic counselors.  
2.2 Qualitative Perceived Economic Burden Of ARVC Study Summary 
A single initial qualitative investigation of the perceived economic burden of 
ARVC is available (Etchegary et al., 2015). This publication was a previous study 
involving members of this research team and comprises interview data from 21 
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individuals including those with an affected, unaffected, or unknown clinical status as 
well as four spouses. Thematic analysis of interview transcripts revealed four major 
perceptions of how ARVC affected their families: i) Economic impact at childhood; (ii) 
Impact on current and future employment; (iii) Impact on current and future financial 
well-being; and (iv) No perceived economic impact.  
Findings for economic impact in childhood suggested that although necessities 
were available like food and shelter, the family often went without “extras.” Additionally, 
children in affected families alluded to having to work in order to supplement their family 
income, some feeling they had to contribute. Experiences of the impact on current and 
future employment included the limitations on the types of jobs that could be safely 
undertaken, time off work for recovery following ICD surgery and narratives that 
revealed how the quality of work was lessened. There were also experiences of spouses of 
affected individuals who returned to work earlier than desired to make up for lost income 
from their family member affected by ARVC.  
With respect to finances, participants noted the effect of the ability to work on 
disposable income, incurring direct costs for treatment for families living outside a main 
treatment center, in addition to worries about financial planning. Concerns over having 
enough insurance or obtaining health or life insurance were voiced, while these worries 
were lessened for those with good insurance plans at work or a supportive employer. A 
few participants experienced no perceived burden, often those who were asymptomatic or 
unaffected but acknowledged that progression may bring forth economic burden in the 
future. 
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Despite identified study limitations, such as small sample size, this initial novel 
investigation provides invaluable insight into the perceived economic burden experienced 
by ARVC patients and families. Results from this investigation provided one major 
component informing the planning and construction of the perceived economic burden 
scale used in this study.  
2.3 Measures of Economic Burden 
The majority of economic studies measure the economic impact of diseases on a 
macroeconomic scale, such as disease costs on the medical system or society. While few 
such studies exist on the economics associated with ARVC, there is a limited body of 
literature consisting of cost-benefit analysis of inherited cardiac arrhythmias 
(Goldenberget al., 2005) or prevention of sudden cardiac death using ICDs (Deniz et al., 
2009). However, for the purpose of this study, these studies are out of scope as they relate 
to determining optimal treatment costs for the medical system using a macroeconomic 
approach. 
 This study takes a microeconomic approach from the perspective of the at risk 
individual and their family. It is concerned with exploring the perceived economic burden 
for patients and their families. Costs incurred by the acquisition of health goods and 
services as a consequence of disease can significantly impact the ability of individuals 
and their families to purchase and consume other goods and services (World Health 
Organization [WHO], 2009). Microeconomic studies are important because if people are 
consuming healthcare, losing money because of a disease or illness, or are unable to 
obtain insurance, they have fewer resources for other non-medical goods and services 
such as food, clothing, housing and leisure/social activities. Therefore, the presence of an 
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economic burden caused by ARVC would affect both individual and family economic 
welfare defined by the WHO (2009) as the ability to consume non-health goods, services, 
and leisure activities. Also there is the stress associated with living with this condition. 
This must pose an enormous, yet difficult to measure burden on individuals and their 
families. 
Currently, there is a limited literature specifically addressing the microeconomic 
burden of the ARVC population from the perspective of affected individuals. The above 
mentioned work of Etchegary et al. (2015) remains the only available research on this 
topic. Despite the lack of research on the microeconomic burden of ARVC, it is possible 
to extrapolate findings from microeconomic studies related to chronic diseases and other 
inherited diseases to the ARVC population. Based on the literature review it appears 
reasonable to conclude that ARVC patients and families will perceive significant 
economic burdens.  
Within the context of a microeconomic approach, various measures of economic 
burden are reflected in the literature. Suhrcke et al. (2006) propose four main categories 
in which the health status of individuals relates to the microeconomic environment. First, 
labour productivity as a means of assessing the effect of health on earnings and wages; 
second, the effect of health on labour supply including employment, hours worked, and 
the probability of retirement; education as part of the human capital theory, and savings 
and investment make up the third and fourth channels where health affects the economics 
of households, patients, and families.  
The categories presented in the work by Suhrcke et al. (2006) are in line with 
those presented in the WHO guide to identify economic consequences of disease and 
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injury  (WHO, 2009). The WHO guide includes five measurement categories for 
microeconomic studies including; expenditures on health by households, labour 
productivity loss, effects on human, physical, and financial capital formation, 
consumption of home-produced goods and services (non-market consumption), and, 
consumption of non-health goods and services (economic welfare). Insurance is a 
common theme discussed throughout the WHO guide, particularly within household 
health expenditures category. Although some variations in terminology exist, there tends 
to be consensus within the literature supporting these measurement categories (Bloom & 
Canning, 2000; Stuckler & Siegel, 2011).  
The limited research into the economic burden of ARVC and genetic conditions 
more generally requires this study to broadly investigate all possible areas for economic 
burden that could affect individuals who are at risk for, or who are known to be living 
with ARVC. The economic categories presented by Suhrcke et al. (2006) are the most 
comprehensive representation of economic burden topics reflected in the literature. These 
categories, with slight modifications and the addition of themes from Etchegary et al. 
(2015), provide the basis for the microeconomic measures used in this study. The five 
measures of economic burden selected for this study are therefore: (i) human capital 
attainment; (ii) labour supply and productivity; (iii) investment and savings; (iv) financial 
burden; and (v) insurance. 
2.3.1 Human Capital Attainment  
Human capital is the term introduced by Shutlz (1961) that suggests an investment 
in education and training increases an individual’s skills and knowledge that, in turn, 
affect their capabilities to conduct productive work. Shutlz concludes that an investment 
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in human capital yields an increase in future wages and income. Human capital theory 
continues to be widely accepted among economists who agree that increased education 
levels result in increased chances of employment and higher wages/salaries.  
Expanding on the notion of investment in education and training, it is likely that 
choices relating to careers may also contribute to future higher wages/income. As such, 
these choices, in theory, contribute to human capital investment. Studies exist that 
demonstrate how education as a component of human capital investment/attainment can 
be directly affected by health status. No current literature, however, discusses career 
choices as a component of human capital attainment affected by health uncertainty, and 
therefore this study is the first, to our knowledge, to include career choices as a 
component of human capital.  
 A reciprocal relationship exists between education and health, where a higher 
level of education is linked to better health status, but also where poor health status is 
linked to lower educational performance, progress and completion. Most studies on the 
relationship between health status and education occur at the primary and secondary 
school levels, ages where ARVC has not normally manifested, nor has testing occurred. 
As a result, these studies will not be discussed in detail.  
 A US study conducted by Teachman (2012) demonstrates the influence of health 
status on education choices in an age group relevant to ARVC. Teachman (2012) 
followed over 10,600 participants aged 19-21 for a duration of 25 years, collecting data 
on post-secondary school enrollment and self-reported health status. He argued that the 
likelihood of post-secondary school enrollment is dependent on the nature of limitations 
on future work caused by disease. Specifically, he examines the effect on two forms of 
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limitations; limits on the kind of work that can be performed and limits on the amount of 
work that can be performed. He argues that diseases limiting the kind of work that can be 
performed increase the odds of post-secondary enrollment by approximately 15%. On the 
other hand, he argues that diseases that limit the amount of work that can be performed 
decrease the odds of post-secondary enrollment by approximately 25%. ARVC has the 
potential to limit both the type and amount of work performed by those at risk, yet it is 
not known which limitation is more prevalent within this population. 
Cervellati & Sunde (2005) suggest that the acquisition of human capital is 
influenced by two main factors - the ability to acquire education and training and life 
expectancy. As previously discussed, those at high risk for ARVC experience shorter life 
expectancies, particularly men, yet the impact of ARVC on human capital attainment is 
not currently reflected within the literature. Oster et al. (2013a) examine how life 
expectancy influences human capital attainment in Huntington disease patients, a genetic 
degenerative neurological disease similar to ARVC in its mode of inheritance, the 
severity of disease, disease penetrance and variable expressivity. One major difference to 
note, however, is that ARVC has a number of effective treatments (particularly ICD 
implantation), whereas Huntington Disease has none. Oster et al. (2013a) found that 
patients who tested positive for the Huntington mutation completed less education and 
were 30% less likely to complete post-secondary education than those who were not 
tested or who tested negative for Huntington Disease. Education was not affected when 
genetic testing occurred at older ages when education is presumed to have been 
completed.   
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Age of onset of symptoms is another predictive factor for the education attainment 
of Huntington disease patients (Oster et al., 2013a). Symptoms beginning in the teenage 
years decrease the likelihood of enrollment in post-secondary education, whereas those 
who develop symptoms between 19 and 28 years of age are at the same likelihood of 
enrolling in post-secondary education as the general population, yet are less likely to 
complete it (Oster et al., 2013a).  
 Similar to genetic conditions, heart disease appears to have a restrictive effect on 
education for those in young adulthood. An Australian study on heart disease patients 25-
64 years of age reports that about half of heart disease and cardiovascular disease patients 
had their education restricted by their condition (Callander et al., 2013). These results, 
however, reflect combined restrictions on education and employment and therefore may 
not represent the true effect on education alone.  
Concerns over career choices within families with known genetic conditions 
appear to begin early in life. Parents of children with genetic conditions have concerns 
about the future employment and career opportunities for their children (Gallo et al., 
2007). These concerns reflect the possibility that their children would be limited in the 
pursuit of certain careers and potential employment limitations caused by their genetic 
condition.  
For ARVC patients, career limitations are likely based on the physical limitations 
required for the management of disease progression and prevention of SCD. Physical 
limitations instilled for disease management may result in ARVC patients choosing 
different professions and/or careers or even require a change in pre-existing careers. To 
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date, only limited qualitative findings exist to indicate whether education or career 
choices are impacted for those at risk for, or affected with ARVC (Etchegary et al., 2015). 
2.3.2 Burden on Labour Supply and Productivity 
Studies discussed below have shown that people suffering from illness and disease 
work fewer hours, miss more work, leave paid employment, earn less income, and are 
more likely to retire at younger ages. These factors, commonly referred to as indirect 
costs, comprise the economic burden on an individual’s labour supply (hours worked, 
employment status, retirement probability) and their labour productivity (wages, earnings 
and income). Some suggest that the burden of disease on labour supply and productivity 
is greater than the monetary amounts spent by individuals on the treatment of their 
disease (Grover et al., 2003; Jonsson, 1996).  
2.3.2.1 Illness and Labour Supply/Productivity Burden 
Evidence exists that labour supply and productivity can be affected by illness and 
disease. Pelkowski & Berger (2004) examined the effect of health problems on annual 
hours worked and wages using data from the United States Health and Retirement survey. 
Their study used retrospective longitudinal data on employment histories and health 
experiences to estimate the impact of health on wages and hours worked. Their results 
indicate that males who are permanently unhealthy earn approximately 5.6% less than 
their healthy counterparts. Females with similar health statuses earn significantly less 
with wages 8.9% lower. The opposite effect between sexes is observed with respect to 
number of hours worked. In this instance, hours worked by males are reduced by a larger 
percentage than females at 6.1% and 3.9%, respectively. While permanent illnesses 
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demonstrate an impact on wages and hours worked, temporary health problems have no 
significant impact on either of these factors for males or females. 
Some people may choose to change their employment status from full time to 
fewer hours to adjust for chronic disease or ill health. Yen et al. (2011) conducted a study 
on chronic disease patients over the age of 50 to assess workforce participation among 
older Australians. Of the chronically ill patients studied, 26% indicated that they were 
working part time. Of those, 12% named ill health as the primary reason for working part 
time hours. 
In addition to evidence that ill health reduces wages and hours worked, people 
with chronic disease are less likely to be in any form of paid employment. Gannon and 
Nolan (2003) used cross-sectional data compiled from two Irish surveys to examine the 
impact of chronic disease on labour force participation for people aged 16 to 64. The 
probability of labour force participation was 61% lower for males and 52% lower for 
females whose chronic illness ‘severely’ affected their daily activities. For males and 
females whose chronic condition affected their daily activities ‘to some extent’, the 
probability of labour force participation was reduced by 29% and 22%, respectively. Not 
only do these findings indicate that chronic disease affects participation in paid 
employment, but they also indicate the role that severity of disease plays in the labour 
force participation of individuals.  
Alavina and Burdorf (2008) studied the associations between self-perceived health 
status and labour participation in ten European countries. Using data from the Survey on 
Health and Ageing in Europe, Alvina & Burdorf found perceived poor health to be 
strongly associated with non-participation in the labour force. Only 18% of the Europeans 
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who reported having poor health remained employed. Poor health, however, is commonly 
reported in unemployed and retired individuals accounting for 39% and 37% of 
individuals with these employment statuses.  
Smith (1999) suggests that people may choose early retirement as a means to 
compensate for ill health. The previously discussed study by Yen et al. (2011) on chronic 
disease patients concluded that 17.3 % of respondents had retired early due to ill health 
with the average age of retirement being 58 years compared to the normal retirement age 
of 63.  Schofield et al. (2008) report a much higher retirement rate amongst chronically ill 
Australians. Their study on premature retirement rates using data from the Survey of 
Disability, Ageing and Careers reports that 46% of chronic illness patients had retired 
prematurely as a direct result of their condition. These results are supported by a similar 
Italian study that reported a significant positive association between chronic disease and 
early retirement (Ranzi et al., 2013).  
Contrary to the majority of literature on the relationship between workforce 
participation, early retirement, and chronic illness, an American study by Miah and 
Wilcox-Gok (2007) reports an opposite effect. Using retrospective data from the 
American Health and Retirement Study, they estimated how chronic illness influences 
asset accumulation and subsequent retirement. Asset accumulation in this study referred 
to the sum of household assets, social security benefits and expected retirement benefits. 
As a result of their analysis, they inferred that chronic illness is associated with reduced 
likelihood of retirement, which they argued is attributable to lower asset accumulation. 
Available literature suggests that living with ARVC may contribute to a reduction 
in wages/income, hours worked or a cessation of employment altogether. Furthermore, 
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decisions concerning retirement may also be affected. These questions have yet to be 
studied in ARVC populations; however, the following section presents evidence from 
diseases with some similar characteristics to ARVC. 
2.3.2.2 Evidence in Heart & Genetic Diseases 
In the absence of microeconomic studies specific to ARVC, it is possible to draw 
similarities to existing studies related to other heart and genetic diseases. By examining 
similar studies of these related chronic diseases, it is reasonable to assume certain trends 
can be applied to ARVC. A single Canadian study examined the effect of heart disease on 
labour supply and productivity. Using cross-sectional data from Statistics Canada’s 
National Population Health Survey, Johansen (1999) studied characteristics of the 
working- age population aged 35 to 64, with and without heart disease. The author 
reported that only 48% of men with heart disease in the working-age population worked 
for pay, compared to 83% of men without heart disease. A similar effect was reported for 
women, where 36% of women with heart disease report working for pay compared to 
64% without heart disease. The primary reason for heart disease patients not working is 
due to recovery from illness connected to their heart disease. Almost one third of heart 
disease patients (30%) reported being on disability compared to only 6% of non-heart 
disease patients. Even though not statistically significant, Johansen indicated that 17% of 
working-age heart disease patients reported being retired, more than double the figure 
(8%) for those without heart disease. 
An Australian study measured various disadvantages experienced by those with 
heart disease, other circulatory diseases and no health condition. Their study used data on 
patients 25 years of age and older from the Survey of Disability, Ageing and Careers. 
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Once adjusted for age and gender, the odds of heart disease patients having low income 
were twice as high compared to people with no health condition (Callander et al., 2013). 
It is not surprising then that half of the heart disease patients in their study reported 
having employment restricted by their condition offering a potential explanation for lower 
household incomes.  
A British qualitative study on the perspectives of patients living with heart failure 
and their caregivers coincides with quantitative results on the effect of heart disease on 
labour. Pattenden et al. (2007) interviewed 36 patients and 20 caregivers using semi-
structured questions to explore participants’ experiences of living with heart failure. It 
was found that many patients indicate an inability to work, whereas only a limited 
number of caregivers report having to giving up work.  
Few studies have demonstrated the effect of genetic conditions on labour supply 
and productivity, yet one study reveals that trends in early retirement are similar to those 
reported in general chronic illnesses. Oster et al. (2013b) conducted a study on behaviors 
of Huntington disease patients as a result of their genetic mutation results. They report 
that patients carrying the gene mutation for Huntington disease were more likely to retire 
early compared to those who did not have the mutation (Oster et al., 2013b).  
2.3.2.3 Labour Supply & Productivity Burden in Family Members 
Similar to unhealthy patients, healthy family members may also experience a 
burden on their personal labour supply and productivity as a result of the presence of 
illness in the family. Studies have indicated spouses and children of ill family members 
experience labour burden reflected in changes to labour supply and productivity. These 
burdens are most often reported in literature where healthy family members become 
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informal caregivers, such as the case for heart failure patients in the Pattenden et al. 
(2007) study presented in section 2.3.2.2 above. 
 Not all changes to a healthy family member’s labour supply or productivity 
reflect cases of leaving the workforce to become an informal caregiver. For example, 
Smith (1999) suggests that even though a decrease in earnings from an ill household 
member may occur, attempts to compensate for this loss by a spouse increasing their 
work may occur. Spousal compensation is evident in a study on female spouses of 
chronic pain patients conducted by Kemler and Furnee (2002) who report a change in 
labour responsibilities within the family. They indicated that the female spouses increased 
their employment to make up for the income and productivity losses of their ill spouse. 
Females have also been shown to have different probabilities of retirement as a result of 
their spouse’s illness. Jiminéz-Martin and Martinez-Grando (1999) reported that a female 
whose spouse is out of the labour force due to chronic illness has a reduced probability of 
retirement by 24%.   
Contrary to females, a male whose spouse is out of the labour force with a chronic 
condition has an increased probability of retiring by 13%. This gender trend is also 
observed with respect to labour supply in a study on spousal reactions to ill health using 
data from the American Health and Retirement survey. In this study, Charles (1999) 
reports that males reduce their labour supply substantially when their spouse encounters 
ill health, whereas females tend to substantially increase their labour supply in similar 
situations. It appears that the spousal trends reflect that males become caregivers while 
females become “breadwinners” in response to chronic disease. 
 
	   33 
2.3.3 Savings and Consumption 
 Illness and disease are shown to affect both the rates at which people save money 
(financial planning) and also consume (spend money) health and non-health related goods 
and services. Financial planning in the form of savings is relatively straightforward; 
however, consumption in the context of this study focuses on two main concepts; (i) out-
of-pocket costs related to ARVC health goods and services; and (ii) general spending 
habits. Although both savings and consumption appear to be affected by ill health 
individually, relationships between savings and consumption as a result of ill health are 
also reflected in the literature below.  
2.3.3.1 Ill Health and Savings 
A bi-directional relationship between health and wealth is widely recognized 
within the literature; where ill health affects the accumulation of wealth, and where 
wealth increases the likelihood of being healthy. Smith (1999) argues that savings 
decrease as health deteriorates due to a potential reduction in income and increase in 
expenditure on health and health-related expenses. A direct effect of health on savings 
exists if a disease forces households to utilize existing or anticipatory savings to finance 
health expenditures (WHO, 2009).  
Historically, some studies exist that link future health uncertainty and savings 
behaviour, commonly referred to as precautionary saving (Lillard & Weiss, 1997; 
Palumbo, 1999). More recently, an Italian study by Jappelli et al. (2007) implied that 
health risk has an important effect on saving rates. Using socioeconomic data from two 
cycles of the Survey of Household Income and Wealth and self-reported health status 
data, the authors concluded that people at risk of falling into poor health save more. 
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Factors such as fewer children and higher income are shown to reduce savings rates, 
whereas increased health, higher education levels and larger families tend to increase 
savings rates (Jappelli et al., 2007). 
One theory presented by WHO (2009) states that people with good health 
generally have longer life expectancies and, as a result, the increased likelihood of 
achieving retirement. They expand on this theory to state that the increased likelihood that 
a healthy person will reach retirement causes that individual to save more money in order 
to guarantee income in their retirement. Contrary to good health and longer life 
expectancies, the WHO (2009) does not indicate whether ill health or a shorter life 
expectancy would result in fewer savings. The authors did, however, suggest that ill 
health may lead to possible savings as households account for future healthcare or non-
health related needs (precautionary saving).  
 Schofield et al. (2012a) concluded in their Australian study that people who retire 
early due to heart disease face long term financial disadvantages compared to people who 
remain in full time employment. Those who had retired early due to heart disease had 
accumulated 99.6% less savings by age 65 compared to those who remained in the 
workforce full time (Schofield et al., 2012a). Their study demonstrated a relationship 
between early retirement because of heart disease and inadequate accumulated savings. 
Based on the current literature, the effect of ARVC on savings remains unknown. 
Precautionary savings may be evident in the ARVC population as the disease 
characteristics indicate ill health in all affected individuals, in addition to a known 
reduction in life expectancy. This study attempts to provide insight into the effect of 
ARVC on savings. 
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2.3.3.2 Out-of-Pocket spending on Health Related Expenses 
For the purposes of this study, out-of-pocket costs will refer to monetary 
transactions for medical (hospital services, physician services, drugs, medical devices, 
homecare) and non-medical (transportation, accommodation) products and services. In 
the literature, these costs are commonly referred to as direct costs, since they are directly 
related to the treatment of a disease or illness. Despite public health funding for all, and 
extended private coverage for many Canadians,5 most households report having out-of-
pocket health expenditures on health care services or products. Out-of-pocket health 
expenditures reduce monetary resources available for households to spend on non-health 
goods and services, as well as a reduction of current and future savings. 
A recent Statistics Canada article by Sanmartin et al. (2014) revealed that out-of-
pocket health care expenditures for Canadian households are increasing, particularly for 
lower income households. Using annual6 data from the Survey of Household Spending 
(SHS) between 1997 and 2009, the authors analyzed out-of-pocket expenditures by 
income quintiles. They found that out-of-pocket spending increased in all income 
quintiles for insurance premiums and prescription drugs, with the largest increases 
occurring in lower income-households. This article demonstrated that Canadians 
experience a certain level of out-of-pocket costs related to their health, regardless of 
public insurance and other government assistance programs. What this article does not 
indicate, however, is the potential differences experienced in households with a family 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  See section 2.5 for details on public and private insurance	  6	  SHS data is collected annually in the 10 provinces, and bi-annually in the territories.	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member who suffers from a chronic disease, but it is likely that lower income individuals 
would be more adversely affected.   
  McGillion et al. (2008) used data collected on chronic angina patients enrolled in 
a self-management program in Ontario, Canada to determine the short-term financial 
impact of their program on their patients. Even though the objective was to demonstrate 
the impact of an intervention program on costs, they calculated an estimate of the annual 
cost of illness for chronic angina patients. Total annual out of pocket costs included 
money paid to health care professionals related to homecare; costs to attend healthcare 
appointments outside of the home (e.g., travel); angina-related medication; and 
supplies/equipment related to heart disease. The mean annual out of pocket costs amount 
to $3,265, ranging from $0 to $40,908. Although their results may not be generalizable 
outside of their chronic angina patients enrolled in their program, the study is one of few 
that provide insight into out-of-pocket costs for heart disease patients in Canada. 
Conrad et al. (2006) conducted a study to determine the economic burden faced by 
heart-failure patients from thirteen American outpatient clinics. Both cross-sectional and 
longitudinal analysis were used to measure health status and perceived economic burden. 
Their results indicated that 44% of patients perceived their medical costs as creating a 
significant economic burden. Those patients reporting economic burden were usually 
younger and more likely to have a lower household income. They also concluded that 
patients who perceived economic burden reported a lower health status compared to those 
experiencing no economic burden. 
Despite the lack of evidence pertaining to ARVC in this area, out-of-pocket costs 
for travel, medication or other health related goods/services related to ARVC are incurred 
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by patients. Such costs have not only been shown to occur but also pose a 
financial/economic burden in many heart disease patients presented in literature thus far. 
2.3.4 Insurance  
 Insurance coverage provides individuals with protection against major financial 
losses as a result of illness, disease, disability or death. Within Canada, both public and 
private health insurance plans exist in the form of a publically funded health care system 
and private supplemental medical insurance as described in the following sections. Even 
though a variety of insurance types exist, the focus in this study is public and private 
medical insurance with additional possible references to life insurance and disability 
insurance.  
2.3.4.1 Canadian Health Care System 
In Canada, a publically funded universal health care system is legislated under the 
Canada Health Act (CHA) of 1984. Public funding utilizes a proportion of federal 
revenue from consumption and income taxes as the main resource for the provision of 
health care services provided to residents (Hurley & Guindon, 2008). The CHA requires 
provinces and territories to provide medically necessary health care services to their 
residents using funds received from the Federal Government through the Canada Health 
Transfer7. In order to qualify for the transfer, provincial and territorial public health care 
plans must comply with five main principles: public administration, comprehensiveness, 
universality, portability and accessibility (CHA, 1984).8 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  7	  Health care services funded directly by the Federal Government for First Nations people living on 
reserves; Inuit; serving members of the Canadian Forces; eligible veterans; inmates in federal penitentiaries; 
and some groups of refugee claimants (Health Canada, 2012b).	  
8 Descriptions of the five main principles can be found in Appendix B.	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Physician and hospital services fall under the umbrella term “medically 
necessary” health care services, which are required to be publically funded. All physician 
costs (consultation, laboratory tests, administration of medication, treatment etc.) as well 
as in-hospital costs (standard accommodation, food, equipment, non-physician care) are 
publically funded services nationwide. In addition to the coverage of services noted 
above, provinces and territories have the option to either partially or fully fund additional 
health services for their residents. Coverage of such supplemental services is usually 
targeted towards certain groups such as seniors, children or low-income residents and 
often includes out-of-hospital prescription drugs, ambulance costs, dental and vision care, 
medical equipment and various health professional services (Health Canada, 2012a). 
 Even though provincial healthcare plans cover many of the healthcare costs, 
public funding only accounts for 70% of the total health expenditure in Canada (Paris et 
al., 2010). Private payers composed of patients and private health insurance companies 
incur all remaining health expenditures contributing 14.9% and 12.8%, respectively (Paris 
et al., 2010). Private health expenditures include costs for out of hospital 
prescription/over the counter drugs, medical equipment, dental and vision care, private 
health professional services (physiotherapy, dentistry, specialty nurse etc.) in addition to 
medically related transportation and accommodation costs. 
 Generally, additional provincial government subsidies are available to supplement 
provincial public health plans, with observed variations between provinces. In the case of 
Newfoundland and Labrador, the Department of Health and Community Services offers a 
variety of financial assistance programs to prevent catastrophic financial spending on 
health services. These programs commonly require specific qualification criteria, usually 
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demographic characteristics, such as specific age or income groups. Provincial programs 
in Newfoundland potentially available to ARVC patients include: Prescription Drug 
Programs, Medical Travel Assistance Program; and Special assistance program – Medical 
equipment and supplies (Government of Newfoundland and Labrador, 2014). Even 
though utilization of these government programs is not directly measured in this study, 
they represent important considerations in the overall financial burden of ARVC as 
possible protective factors. 	  
2.3.4.2 Private Medical Insurance 
In addition to public insurance, 67% of Canadians are enrolled in extended private 
health insurance plans (Paris et al., 2010). The primary role of private insurance is to 
provide complementary coverage for services not covered by the publically funded health 
care system. Approximately 91% of extended health care insurance coverage in Canada is 
offered by way of a group plan such as part of an employee benefits package in which 
many employers pays insurance premiums9 (Canadian Life and Health Insurance 
Association [CLHIA], 2013). It is possible, however, for those who are self-employed, 
unemployed or without group plans to purchase an individual insurance plan, usually at 
significantly higher premiums (Hurley & Guindon, 2008). In addition to elevated 
premiums, individual extended health plans often exclude expenses incurred as a result of 
pre-existing medical conditions (CLHIA, 2012). 
Extended healthcare plans range in their coverage of eligible expenses yet 
typically do not pay 100% of the covered costs. Normally, plans require a deductible 
(commonly $25-$50, per individual), a co-pay (usually 10-20%) and/or limit the 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9 Premiums refer to rates charged for insurance coverage 
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maximum monetary amount an insured member can claim for a given time period 
(CLHIA, 2012). Depending on the type of plan, eligible expenses consist of various 
combinations of costs for prescription drugs, semi-private or private hospital 
accommodation, special nursing services, ambulance services, medical appliances or 
equipment, medical services excluded from government plans (e.g. services from 
chiropractors, physiotherapists, optometrists etc.), and vision care (CLHIA, 2013).  
The exact methodology used by insurance companies to calculate individual 
amounts paid for premiums, deductibles, co-pays or maximums is highly proprietary. It is 
likely, however, that factors such as age, health status, medical history and assessment of 
“risk” for the insurance company, factor into premium rates. It is important to note that no 
federal or provincial regulation exists in Canada to control the premiums that private 
insurance companies can charge for health insurance (Hurley & Guindon, 2008). In 
addition to the potential for elevated premiums, previous medical histories may also 
affect eligibility for health insurance, rendering the purchase of private health insurance 
increasingly challenging for some individuals.  
2.3.4.3 Life Insurance 
Approximately 22 million Canadians are enrolled in a life insurance policy 
(CLHIA, 2015b). Although a variety of life insurance policies exist such as term or whole 
life insurance, the purpose of life insurance is to protect families against financial 
hardship in the event of death (CLHIA, 2015a). The provision of life insurance is similar 
to previously discussed private medical insurance as both individual and group coverage 
are available, yet the focus of assessment is on mortality rather than illness or disease. 
Insurance companies make long term projections based on statistical or actual experience 
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of mortality rates suggesting the risk for future expense and to calculate interest rates 
(CLHIA, 2015a). Like extended medical insurance, risk stratification remains highly 
proprietary and depending on the risk stratification of an individual, they may be required 
to pay higher premiums or be denied life insurance.  
2.3.4.4 Genetic Discrimination  
Genetic discrimination refers to the discrimination against an individual or 
members of their family on the sole basis of actual or perceived genetic differences rather 
than physical features (Billings et al., 1992). Discrimination can occur with respect to 
employment, medical, life and other types insurance, and even socially. For our study, 
genetic discrimination is mostly assessed on the basis of medical/life insurance, and is the 
focus of this review. 
Currently, no legislation exists in Canada that protects individuals specifically 
against genetic discrimination despite wide recognition of the issue and precedents set 
internationally. In fact, Bill C-508, which was introduced in 2010 proposing amendments 
to the Canadian Human Rights Act to include genetic characteristics as a prohibited 
grounds for discrimination did not pass. Internationally, many countries have enacted 
laws to protect or limit the use of genetic information for insurance purposes. For 
example, in the United States, the Genetic Information Nondiscrimination Act (GINA) 
enacted in 2008, protects individuals against genetic discrimination with regards to 
employment and health insurance (U.S Department of Health and Human Services, 
2008). In the Canadian context, Pullman and Lemmens (2010) argue that the provision of 
essential health services under the current public health care system does not warrant a 
need for statutes such as GINA at this time in Canada. They do, however, recognize that 
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genetic technology could be used inappropriately to affect at-risk individuals in contexts 
such as life or disability, or additional health insurance. It is important to note that the 
GINA statute does not prohibit discrimination with regard to life or disability insurance. 
In a position statement on genetic testing, The Canadian Life and Health 
Insurance Association (CLHIA) indicated that the policy of the Canadian private 
healthcare or life insurance industry does not require an insurance applicant to undergo 
genetic testing (CLHIA, 2010). Conversely, this does not prevent such practices nor does 
it prevent the use of pre-existing genetic information. For example, the CLHIA 
recognizes the use of pre-existing genetic test results by insurance companies as 
equivalent to information pertaining to family history.  
2.3.4.5 Genetic Discrimination in the Literature 
No studies were found on cases of genetic discrimination for ARVC patients or 
related inherited cardiomyopathies. Huntington disease was one of the first genetic 
conditions utilizing genetic testing and as a result is the focus of much of the literature in 
this area. A Canadian cross sectional study of asymptomatic Huntington patients by 
Bombard et al. (2009) used self-reported data to assess perceived genetic discrimination. 
Genetic discrimination was perceived by about 40% of Huntington respondents. The 
majority of discrimination was in relation to insurance where 29% of respondents 
perceive genetic discrimination; other areas indicate discrimination by family (15%) 
socially (12%) and less often in employment/healthcare. Insurance discrimination is 
described in the form of insurance rejection, premium increases, or requests to take 
predictive tests. The study also reports that the main reason for discrimination is family 
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history, where a significantly smaller proportion of respondents attribute their 
discrimination to actual genetic test results. 
For Huntington patients in Australia, Canada and the United states, genetic 
discrimination is reported by 26% when trying to purchase any type of insurance, while 
over 70% patients worry about being denied insurance (Erwin et al., 2010). This study 
also confirmed that discrimination occurs because of genetic test results and family 
history of the disease. Another study conducted by Bombard et al. (2011) on Huntington 
disease patients used cross sectional data to explore the factors associated with having 
experienced genetic discrimination. Factors that increased the likelihood of genetic 
discrimination included higher education, risk identification at a younger age and a 
mutation positive status. 
More than half of the parents of children with genetic conditions raised concerns 
in a qualitative study over health insurance, stating issues of having claims denied, 
reaching lifetime maximums and not being able to obtain insurance because of pre-
existing conditions (Gallo et al., 2008). This concern was also mirrored with respect to 
life insurance for this population.  
ARVC patients may encounter elevated insurance premiums as well as the denial 
of medical or life insurance on the basis of genetic discrimination or reported 
medical/family history. It seems possible to expect these findings in the ARVC 
population based on reported evidence from other genetic conditions such as Huntington 
Disease. Many similarities exist between Huntington Disease and ARVC, yet perhaps the 
most important similarity to note is that both are genetic conditions identifiable with 
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available genetic testing. It is therefore expected that the ARVC population will 
experience similar problems with purchasing medical or life insurance. 
2.4 Summary 	  
ARVC is a severe and often lethal inherited disease of the heart muscle with 
variable disease progression affecting approximately 1 in 2000-5000 in the general 
population. The disease is likely more common in Newfoundland families where the 
disease is caused by a p.S358L mutation in the TMEM43 gene. This disease is known to 
cause a variety of symptoms in affected patients, the most notable of which is SCD. 
ARVC caused by a p.S358L mutation in TMEM43 is highly sex-influenced where men 
experience more severe symptoms at earlier ages in addition to significantly reduced life 
expectancies in the absence of treatment. Advancements in both diagnostic criteria and 
techniques such as genetic mutation analysis have enabled the early detection of the 
disease in at risk populations, allowing clinical management of the disease using 
medications, ICDs and sometimes surgery.  
There is a significant gap in existing literature pertaining to the economic burden 
experienced by ARVC patients and their families. Previous qualitative work by members 
of this research team has identified perceived burden for ARVC patients including 
experiences beginning in childhood, employment limitations and disruptions, financial 
concerns and problems with insurance. Despite the limited research into the 
microeconomic burden of ARVC, it is possible to extrapolate findings from studies on 
conditions with similar disease characteristics to ARVC when determining the possible 
economic burdens experienced by this population. Relevant literature indicates that 
chronic disease, ill health, health uncertainty, life expectancy, and genetic predisposition 
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are all contributing factors to changes or burdens within the economic measures used in 
our study. These measures include (i) human capital attainment; (ii) labour supply and 
productivity; (iii) consumption and savings; (iv) financial burden and (v) insurance.   
Any perceived economic burden experienced by ARVC patients and their families 
has the potential to disrupt various aspects of their lives and contributes an additional 
burden to families already facing a severe and fatal disease. It is therefore imperative to 
conduct research in this area. Available literature on the various economic burden areas 
being examined in this study provide sufficient evidence to indicate a possible economic 
burden experienced by ARVC patients and their families. This study attempts to address 
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Chapter 3: Methods 
3.1 Survey Instrument 
Objective one of the study was to develop a survey tool to collect data on the 
perceived economic burden of ARVC caused by the p.S538L mutation in TMEM43 in the 
Newfoundland population. Survey instrument development began with the identification 
of general themes and topics thought to contribute to perceived economic burden based 
on prior qualitative interviews with ARVC families (Etchegary et al., 2015). Findings 
from this study were used to identify general topics and themes pertaining to economic 
burdens experienced by participants.10 The qualitative data focused on participants’ 
thoughts about growing up with ARVC in their families or marrying into a family with a 
history of ARVC and how this influenced their family's spending, education and career 
choices and other economic factors.  
The study conducted by Etchegary et al. (2015) found that most families could 
afford necessities such as food, clothing or shelter but identified a lack of disposable 
income for non-essential spending ranging from toys or entertainment supplies to family 
vacations or buying brand named. They recalled how their unaffected parent (usually 
their mother) had to take on extra work as a result of the loss of income from their 
affected father. As adults, participants noted how ARVC affected their ability to work, 
and as such, their disposable income. Similar to findings in parents, spouses of affected 
individuals indicated having to return to work or increase work hours to compensate for a 
reduction in family income caused by their affected spouse’s work limitations. Other 
participants discussed the expense of managing ARVC, particularly those who had 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
10 A detailed summary of this investigation is presented in Section 2.2 
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to travel to the Health Sciences Centre in St. John’s for treatment, appointments, and 
following a cardiac event ( e.g a shock from their ICD). Finally, others noted their 
difficulty securing additional life or health insurance and their worry for their children's 
eventual ability to do so. 
The approach to participant consultation in survey development was the use of 
existing qualitative data from Etchegary et al. (2015). 11 In addition to pre-existing 
qualitative data, topic development focused on consultation with various clinicians who 
provided patient experiences from anecdotal evidence. Finally, literature was explored to 
supplement, structure and finalize topics leading to the drafting of survey items. Once 
survey items were drafted, additional input was sought from various experts in the field 
resulting in minor changes to content, question structure, and editorial changes. The final 
version of the survey was reviewed and agreed upon by the academic supervisory 
committee.  
 A five point Likert scale was selected as the most appropriate to provide self-
reported descriptive data. Higher scores indicate a greater perceived burden. Data 
gathered by the survey instrument reflected topics in areas such as perceived burdens, 
experiences and beliefs pertaining to education and career choices, indirect and direct 
costs, insurance, and finally finances, all related to a respondent’s personal and familial 
risk for ARVC.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11 Direct consultation with participants specific to this quantitative study was not conducted due to the pilot 
nature of the project, ethical considerations of the known research burden within this population, and 
academic time constraints.  
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The final survey instrument comprised eight sections (education choices, career 
choices, personal indirect costs, indirect costs for other family members, income, direct 
costs, insurance, and finances/spending) with a total of 76 items.12 Respondents were also 
given the opportunity to respond to an open-ended question on the final page of the 
survey instrument that facilitated the collection of any information they believed to be 
pertinent to economic burden not covered by the existing questions. The final component 
to the survey was a five-question demographic sheet collecting information about 
respondents on their education level, employment status, marital status, number of 
children and income. The survey was estimated to take respondents approximately 20-30 
minutes to complete.  
3.2 Study Population 
A Cardiac Genetics Clinic located at the Health Sciences Center in St. John’s 
Newfoundland, manages the testing and treatment of families at risk for ARVC. As such, 
there is an extensive, previously established population from which a sample was 
selected. The ongoing clinical research of ARVC in Newfoundland for over 30 years has 
identified 25 family pedigrees expressing ARVC caused by the p.S538L mutation in the 
TMEM43 gene. These 25 families account for 885 individuals all of whom were born at 
an a priori 50:50 risk of inheriting ARVC causing P.S538L mutation in TMEM43.  Both 
research and clinical information for these individual family members are maintained in a 
database, which for the purpose of this study will be referred to as the ARVC TMEM43 
registry.  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
12 Readability level of the survey was determined using Microsoft Word © readability function with a 
Flesch-Kincaid Grade level score of 8. Refer to Appendix C2 for original survey and demographic sheet 
content. 
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Purposive sampling utilizing the pre-existing ARVC TMEM43 registry was the 
method selected to identify a population from which to sample. The registry contained a 
total of 885 individuals from 25 families who were further screened based on 
ascertainment and other inclusion criteria. Individuals from four newly identified families 
(n = 34) were excluded from the sample based on considerations of them coping with a 
new diagnosis and the limited amount of data available for these individuals. All potential 
participants were born at an a priori 50% risk of inheriting the ARVC causing p.S538L 
mutation in TMEM43 and were also limited to well-ascertained individuals (n = 699) 
where the clinical status (either affected or unaffected) of ≥ 50% of siblings was known 
(Hodgkinson et al., 2013).  
Those who were poorly-ascertained (n = 152), where clinical status was known 
for < 50% of siblings were excluded from the study (Hodgkinson et al, 2013). Both males 
and females were included in the study and the minimum age for participation was 14 
years. Individuals born at a risk other than 50% of inheriting the ARVC causing mutation 
are not part of the dataset, so are not included. Well- ascertained individuals known to be 
deceased (n = 214) were also excluded from the population. Ascertainment data is 
presented in figure 3.1. Furthermore, to be included in the analysis participants must have 
returned their surveys within the given data collection period of December 1, 2013 to 
May 30, 2014.  
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Figure 3.1 Ascertainment, sampling and data collection occurring between December 1, 
2013 and May 30, 2014 
Total (25 
families) 
n = 885 
Family Included 
Yes (21 families) 
n = 851 
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n = 34  
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n = 214 
Excluded 
Affected 
n = 196 
Unaffected 











n = 98 
Sent Survey Sent Survey 
 
Agreed to Study Agreed to Study 
 
Yes 
n = 38 
No 
n = 54 
Yes 
n = 26 
No 
n = 54 
Yes 
n = 92 
No 
n = 21 
Yes 
n = 80 
No 
n = 37 
	   51 
3.3 Recruitment 
 Well-ascertained individuals meeting inclusion criteria (n = 485) were randomly 
selected from each clinical status group (affected, unaffected and unknown), representing 
approximately half from each group. Potential participants were contacted by phone 
either directly by someone with a pre-existing clinical relationship with the family, or on 
behalf of a clinician by a researcher involved with various ARVC research projects. 
Those opting to receive study documents were then given the option to receive the 
surveys either by mail or electronically in fillable PDF files through email.  
A total of 230 affected and unaffected individuals representing half from each 
clinical status group were contacted and invited into the study. The justification to only 
invite half of the eligible population was determined based on time constraints of the 
academic program, and to isolate the other half of the eligible population for future study 
using the preliminary validated perceived economic burden scale produced by this 
study.13  Of the individuals contacted, 172 agreed to participate and receive study 
documents. A summary of the number of individuals contacted based on clinical status is 
presented in figure 3.1. 
3.4 Data Collection  
Survey packages were sent to participants either by mail or in electronic format by 
email based on participant preference. All packages contained a consent form, the 
economic impact of ARVC survey, a demographic sheet, and a survey for a related study 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  13	  Please note this is an already oversampled population, therefore only contacting half of the eligible 
population was purposefully chosen in order to reduce the risk of research burden.	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on the psychosocial impact of ARVC.14 Refer to Appendix C for a copy of the original 
study documents. Additionally, mail packages included a self-addressed postage paid 
envelope for participants to return their completed surveys. To maximize response rate, 
follow up calls were conducted approximately three weeks following the distribution of 
the survey packages, and an additional mail out to all email participants was also 
completed following problems with document compatibility. Data collection occurred 
from December 1st 2013 to May 30, 2014. 
3.5 Secondary data from the ARVC TMEM43 registry  
The ARVC TMEM43 registry was created in 2004 as a means of tracking 
individuals and families that were at risk of developing the ARVC condition. This effort 
was undertaken to establish not only patient records for this population but also as a 
means to readily access data on this population for research purposes.15 The registry 
continues to be a working research dataset for research projects targeted towards the 
TMEM43 population. In total there are over 1500 variables for each patient containing 
information such as demographics, diagnostic procedures and results, pharmaceutical 
treatments, cardiac interventions, cardiac events, hospital and clinic visits, and clinician 
notes. For the purpose of this study, the registry was used to identify the study sample but  
was also a source of secondary data for information on participant age, sex and ARVC 
clinical status. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
14 The 20-30 minute time estimate for survey completion stated in Section 3.1 was for the economic survey 
only, and not the related psychosocial survey. 
15 This approach to a genetic registry system was based on Emery et al. (1972) and Emery & Brough (1978) 
and the World Health Organization  
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3.6 Data Management 
Data were entered into a de-identified copy of the ARVC TMEM43 registry and 
analyzed using SPSS® statistical software (Version 22). Study participants responses 
were coded using unique identification numbers already established within the ARVC 
TMEM43 registry. Each Likert survey item was coded using its respective score from 1 
(strongly disagree) to 5 (strongly agree), binomial responses were coded as 1 (yes) to 2 
(no) and all N/A (not applicable) responses were coded with a numerical value of 6 and 
excluded from mean calculations. Open-ended responses were transcribed as string data 
in text format and all demographic responses were coded with unique numerical values. 
16All missing data was entered using a numerical value of -99 and were excluded from 
analysis. To improve data accuracy, each entry was cross-referenced twice with the 
original survey and descriptive statistics were run on each item to ensure no invalid 
values were entered.  
3.7 Scale Construct  
 The second objective of this study was to construct and provide some initial 
validation data on the Perceived Economic Burden (PEB) of ARVC scale. The construct 
of the scale began with the assignment of the original 76 survey items into the five 
measures of perceived economic burden reflected in the literature to create five 
hypothesized subscales17. The five hypothesized subscales are: (i) human capital 
attainment (HC); (ii) labour supply and productivity (LSP); (iii) consumption and saving 
(CS); (iv) financial burden (FB); and (v) insurance (IN). Initially, survey items were 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
16 Analysis was not performed on the open-ended string data. Rather, this data will be used to inform future 
studies by members of the research team.  
17 Refer to Table F1 in Appendix F for the assignment of original survey items into hypothesized subscales.	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divided into the eight separate sections to increase readability and simplicity for 
respondents. The grouping of survey questions into the five subscales increased reliability 
values of the survey items in addition to reflecting those presented in the literature.  
Original survey items were examined for face and content validity for each 
hypothesized subscale and distributed accordingly resulting in the exclusion of seven 
original survey items determined to be independent items. The process of item reduction 
occurred through consultation between the author and members of the supervisory 
committee until a consensus was achieved. Furthermore, all binomial survey items were 
excluded from the hypothesized scales for separate analysis. All items in each subscale 
were examined to ensure all were scored in the same direction (i.e., higher response value 
indicated greater burden), which resulted in the reverse coding of one subscale item 
(IN1). The final step prior to scale validation involved the summation of subscale item 
scores, and the calculation of multi-item mean scale scores. The result was a subscale 
score for each participant ranging from 1 to 5.  
3.8 Statistical Analysis 
3.8.1 Survey Response Rates & Representativeness of Sample 
 Response rates for the survey were calculated based on the number of respondents 
with completed surveys and consent forms. Those with incomplete consent forms or 
blank surveys were excluded from the final sample. Demographic characteristics of the 
final sample population were calculated based on complete demographic sheets and 
secondary data obtained from the ARVC TMEM43 registry.  
Descriptive and frequency statistics were calculated to determine the demographic 
information of the study population. Chi-square test for independence was performed to 
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determine the representativeness of the study population. The purpose of a Chi-square test 
is to explore the relationship between two or more categorical variables (Pallant, 2010, 
p.215). Using Chi-square tests, select demographic data on all individuals who met 
inclusion criteria were compared to the demographic data of the final sample population. 
Two chi-square tests were conducted to determine representativeness of the sample with 
respect to clinical status and sex. These demographic variables were selected on the basis 
of the completeness of data. A variable would be representative of the original population 
if a significant difference (p < .05) between the original and final sample was not 
observed. Tests for representativeness of a population are useful to determine the 
generalizability of the study results.  
3.8.2 Scale Validation  
 Validation of the scale followed work based on Ware and Gandek (1998) and used 
by others in the testing of scales18. All statistical tests for scale level assumptions were 
conducted using SPSS© version 22. The purpose of scale validation is to provide an 
evaluation of the evidence to support the appropriateness, meaningfulness and usefulness 
of the inferences that can be made from an instrument score (Zumbo & Chan, 2014). 
3.8.2.1 Item level descriptive statistics and subscale score calculation 
The first step in the scale validation involved the calculation of item level 
descriptive statistics for each survey item to determine the amount of missing data, 
frequency of responses, item means and standard deviations. It is expected that scales 
have only a small amount of missing data, all response choices are utilized for each item, 
item means are roughly consistent within each scale item and standard deviations are 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
18 See Watkins et al., 2013; Radwin et al., 2005 
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roughly equivalent and around 1.0 for a five-choice Likert response scale (Ware & 
Gandek, 1998).  
As previously discussed in Section 3.7, multi-item scale scores were computed as 
a mean scale score based on response values from individual items within each 
hypothesized scale. A mean score was used as opposed to a summated scale score based 
on the amount of missing data for individual items and for ease of comparison between 
scales. 
3.8.2.2 Tests for Likert scale assumptions 
 The second step in scale validation involved the creation of a multitrait/multi-item 
correlation matrix to examine the relationship of each item to its hypothesized subscale in 
addition to other subscales (Ware & Gandek, 1998). A multitrait/multi-item matrix 
approach tests three Likert scaling assumptions: (i) item internal consistency; (ii) equality 
of item-scale correlations; and (iii) item discriminant validity. Item internal consistency 
tests the assumption that items should be linearly related to the overall subscale concept 
being measured, and is tested by comparing the correlation of each item score with its 
corresponding overall scale score (computed using the mean scores of all items within a 
given scale). A substantial and satisfactory item internal consistency is considered a 
correlation of 0.40 of an item with its hypothesized scale (Ware & Gandek, 1998). 
 Assumption two, equality of item-scale correlations, tests that scale items 
contribute roughly equal proportions of information to total scale score. This assumption 
was tested by visually inspecting the multitrait/multi-item matrix to determine the extent 
of equality between the correlations of items and their hypothesized subscales. This 
standard is satisfied if all items contribute substantially to the total scale score even if 
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item-scale correlations vary. Ware & Gandek (1998) suggest that it is satisfactory for 
item-scale correlations to vary (e.g., from 0.40 to 0.70) across the same scale. 
The third Likert scale assumption, item-discriminant validity, tests the extent to 
which each item measures concepts other than what it is expected to measure, ultimately 
determining the integrity of the hypothesized item groupings into scales. This assumption 
was tested using the multitrait/multi-item correlation matrix to compare the correlation of 
an item with its hypothesized scale to the correlation of that same item with all other 
scales in the matrix. Item discriminant validity is supported if the correlation between an 
item and its hypothesized scale is significantly higher than its correlation with all other 
scales in the matrix. The significance level for correlation comparison is approximately a 
95% confidence interval determined using two standard errors which is equal to 1 divided 
by the square root of the sample size. The number of item-discriminant tests is equal to 
the number of items in a scale multiplied by the number of scales in the matrix minus 1.  
3.8.2.3 Test for Scale Reliability 
The third step in the validation process involved establishing reliability of 
measurement for each subscale. Ware & Gandek (1998) describe reliability of 
measurement as the extent to which the measured variance in a score reflects the true 
score and not random error. Simplified, the definition of reliability of a subscale is the 
extent to which the measures give consistent and accurate results. Item internal 
consistency, determined by Cronbach’s alpha coefficients, was selected as the method to 
determine reliability of subscales. Cronbach’s alpha coefficient calculation takes into 
account the number of scale items and item homogeneity (Cronbach, 1951). Cronbach’s 
alpha coefficients were calculated for the five hypothesized subscales to determine their 
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internal consistency. Literature suggests that an acceptable Cronbach’s alpha coefficient 
value for group level comparison is 0.70 (Nunnally & Bernstein, 1994). 
3.8.2.4 Correlations between Scales (Validity of PEB Scale) 
 The final step in the validation process involved the evaluation of each subscale to 
determine if each subscale was making a distinct contribution (unique reliable variance) 
to the overall PEB scale. To determine the validity of the overall PEB scale, correlations 
between the five subscales were compared with reliability estimates (Ware & Gandek, 
1998). A subscale is making a distinct contribution if its correlations with the other scales 
are less than its own reliability coefficient (Guilford, 1954). Correlations between two 
scales that have equal reliability coefficients indicate the possibility of scales performing 
like alternate measures of similar concepts (Ware & Gandek, 1998). Ware & Gandek 
(1998) suggest that factor analysis may also be performed to further test construct 
validity; however, as a larger sample size is a requirement for factor analysis it was not 
conducted19. 
3.8.3 Empirical Analysis  
3.8.3.1 Regression Technique and Analysis  
Multiple linear regression is a technique for examining the relationship between 
independent variables (referred to as predictors) and a single continuous dependent 
variable (Aiken, West & Pitts, 2003). Multiple linear regression is typically used to 
explore and maximize prediction for independent variables (Pedhazur, 1997). For this 
study the five mean scale scores (HC, LSP, CS, FB, IN) were selected as continuous 
variables for regression analysis, and as such five distinct regression analysis were 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
19 Final sample size for this study n = 64 
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conducted. Mean scale scores could range from a minimum of 1 to a maximum of 5; an 
increase in the value of the score is associated with an increased perceived burden.  
The suggested practice for the selection of the number of independent variables in 
multiple regression analysis is one independent variable per 15 respondents (Stevens, 
1996, p.72). Due to the pilot and the exploratory nature of the study a larger than normal 
number of independent variables was selected for regression analysis to determine which 
predictors may account for the variation in scale scores. Predictors were chosen based on 
variables that were indicated in literature and also from preliminary data analysis such 
that predictors with low correlations with the dependent variable were not included in 
regression models.  
 Demographic variables were used to suggest potential predictors of perceived 
burden. Predictor variables for regression analysis included sex, clinical status and 
various demographic variables either collected as part of the study or contained within the 
TMEM43 data registry. Many of the demographic predictor variables were re-grouped 
into a smaller number of categories and transformed into binary variables to simplify 
regression model interpretation. The coding for binary variables consisted of a coding 
value of 1 for the category of interest and 0 for all other categories within a given 
predictor type. A value of 1 indicates the presence of the specific predictor attribute; 
conversely, a value of 0 indicated the absence of a predictor. Predictor variables used in 
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Table 3.1 Predictor variables used in multiple regression analysis. 
Predictor Type Category/Description Variable Name Coding* 
Clinical 
Status/Sex 
Affected Male Affectedmale AA = 0 
AP = 1 
Affected Female Affectedfemale AA = 0 
AP = 1 
Unaffected Male Unaffectedmale AA = 0 
AP = 1 
Unaffected Female Unaffectedfemale AA = 0 
AP = 1 
Age N/A Age Continuous 
variable 
Children Has Children? Haschildren 0 = no 
1 = yes 
Education Level Some High School 
(HS) or HS diploma 
eduuptoHS AA = 0 
AP = 1 
Some or completed 
post secondary 
education 
Edupostsecondary AA = 0 
AP = 1 
Employment 
Status 
Employed either full 
time or part time 
employed* AA = 0 
AP = 1 
Retired or 
unemployed 
unemployed_retired AA = 0 
AP = 1 
Income Household Income 
less than $50,000 
incomeless50 AA = 0 
AP = 1 
Household income 
greater than $50,000 
incomegreater50 AA = 0 
AP = 1 
Marital Status Single or divorced single_divorce AA = 0 
AP = 1 
Married or living 
with partner 
married_livingwithpartner AA = 0 






missing_dem AA = 0 
AP = 1 
* AA = Attribute absent ; AP = Attribute present  
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In order to validate the multiple linear regression analysis, a number of 
assumptions regarding the data must be met, such as tests for multicollinearity, normality, 
homoscedasticity and independence of residuals (Pallant, 2010, p.150). Tests for 
multicollinearity examine the relationships between predictor variables to ensure that 
these variables are not highly correlated. To satisfy the multicollinearity assumption, both 
Tolerance scores and Variance Inflation Factor (VIF) values were examined for each 
regression model. To satisfy the multicollinearity assumption, Tolerance scores should 
exceed 0.10 and VIF values should be greater than 10 (Pallant, 2010, p.158).   
Normality and linearity assumptions require that residual values be relatively 
normally distributed and have a straight-line relationship with the predicted dependent 
variable score. These assumptions were tested for each of the regression models by visual 
inspection of the Normal Probability plots. The normality and linearity assumptions are 
not violated if the residual points lie in a reasonably straight diagonal line from the 
bottom left to top right of the Normal Probability Plot (Pallant, 2010, p.158). Finally, tests 
for homoscedasticity assumptions are used to determine if the variance of the residuals 
about the predicted scores are the same for all predicted scores. Homoscedasticity 
assumptions were tested by visually inspecting the residuals scatterplot for each 
regression where all residuals should be roughly rectangular distributed and concentrated 
in the center around the zero point (Pallant, 2010, p.158). 
 Regression analysis was conducted on the five subscales representing the five 
selected areas of economic burden. Table 3.2 presents variables selected for each of the 
regression analyses including reference groups for the dummy variables. 
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Each regression model was examined to determine the proportion of variance explained 
in the dependent variable by the distinct combination of predictors (R square value). The 
test of significance for the R square value is represented by the p value presented in the 
ANOVA table. Regression coefficients (B values) were subsequently examined to 
determine significant predictors for each subscale mean score as indicated by the p value. 
Table 3.2 Variables selected for regression analysis. 
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3.8.3.2 Chi-Square tests for Independence Technique and Analysis 
 Chi-square tests explore the relationship between two or more categorical 
variables (Pallant, 2010, p.217). The test measures how observed cell counts in cells 
diverge from predicted values, where a large difference between expected and observed 
counts is indicative of a significant relationship. Chi-square statistics were selected for the 
analysis of all binomial survey items. A 2x4 table was used to determine whether a 
relationship between clinical status/sex and item responses was present. Tests were on the 
following survey items: Ind13, Ind14, Ind15, Ind16, Indof8, Insur7 and Insur8 (Figure 
C1, Appendix C). Clinical status/sex categorical variables were affected males, affected 
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3.9 Data Merger and Storage 
The original de-identified version of the dataset was merged with the original 
TMEM43 registry dataset for storage of data for 20 years20. Hard copies of the consent 
forms and all survey questions were stored separately in a locked filing cabinet in a 
secure office at the Health Sciences Centre campus of Memorial University of 
Newfoundland. 
3.10 Ethics Approval 
 This study received ethics approval from the Health Research Ethics Board 
(HREB) overseen by the Health Research Ethics Authority (HREA) at Memorial 
University of Newfoundland under reference number 13.096. Full board approval was 
granted October 3, 2013 (Appendix E). Three amendments were submitted to include use 
of email in the study protocol, the additional collection of demographic information and 
the addition of a research team member to enroll participants. The three amendments 
were approved on November 15, 2013, February 6, 2014 and February 13, 2014 












 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
20 Consent forms indicated that data would be kept for 20 years. Participants were able to choose not to 
have their data stored in which case their data was destroyed prior to the data merger. 
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Chapter 4: Results 
4.1 Survey Response Rates 
 Survey response rates are presented in Figure 3.1 in Chapter 3. There were 485 
individuals identified from the ARVC TMEM43 registry (n = 885) who met the study 
inclusion criteria. When contacted, 172 eligible individuals agreed to receive and review 
the study documents of which there were 64 (37.2%) individuals who enrolled in the 
study and 108 (62.8%) non-respondents.21 The final sample consisted of 28 (43.8%) 
affected females, 21 (32.8%) unaffected females 10 (15.6%) affected males, and 5 (7.8%) 
unaffected males. 
4.2 Demographic Characteristics of Sample 
 Table 4.1 describes the demographic characteristics of the sample population in 
this study. The mean age of the population was 52 years (SD 13.92) with a minimum of 
24 years and maximum of 83 years. The largest age demographic in the sample was those 
in the middle age range comprising 41-60 years, representing 45.5% of the sample. More 
than three quarters (76.5%) of respondents were female, with the majority of respondents 
indicating their marital status as married or living with a partner (65.2%). Respondents on 
average had 1.81 children (SD 1.30) with the minimum number of children reported as 0 
to a maximum of 6. Roughly one third of the sample (29.7%) had achieved a non-
university post-secondary education, with high school diploma (14.1%), some university 
(10.9%) and bachelors degree (12.3) educational achievement comprising approximately 
one third of the rest of the sample. The two most frequently indicated employment 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
21 Data collection from December 1st 2013 to May 30, 2014. There were 176 individuals contacted, of 
which four with unknown clinical status (poorly ascertained) were contacted in error and subsequently 
excluded from the study. 
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statuses were employed full-time and retired, which comprised 34.4% and 32.9% of the 
sample respectively. Just over one quarter of the sample (26.6%) indicated an annual 
household income of $26,000-$50,000.  
Table 4.1 Demographic characteristics of study participants. 
Characteristic n   (%)             Range            Mean (SD) 
Age (n=64)                         24 - 83            52.0  (13.92) 
<20 0   (0.0) 
21- 40 16 (24.2) 
41- 60 30 (45.5) 
61- 80 17 (25.8) 
> 80 1   (1.5) 
Sex (n=64)  
Male 15 (23.5) 
Female 49 (76.5) 
Marital Status (n=57)  
Single, Never married 7   (10.6) 
Married or Living with partner 43 (65.2) 
Divorced or separated 7   (10.6) 
Widowed 0   (0) 
Number of Children  (n=57)                          0 – 6                1.81 (1.30) 
Highest education obtained  (n=56)  
Some High School 6   (9.4) 
High School Diploma 9   (14.1) 
Trade School or non  
University 19 (29.7) 
Some University 7   (10.9) 
Bachelor’s Degree 8   (12.5) 
Graduate Degree 4   (6.3) 
Other 3   (4.7) 
Current Employment Status (n=56)  
Employed Full-time 22 (34.4) 
Employed Part-time 8   (12.5) 
Student 0   (0) 
Retired 21 (32.8) 
Unemployed 5   (7.8) 
Annual Household Income (n=55)  < $25,000 8  (12.5) 
$26,000 - $50,000 17 (26.6) 
$51,000 - $75,000 12 (18.8) 
$76,000  -$100,000 6  (9.4) 
> $100,000 10 (15.6) 
I’d Rather Not Say 2  (3.1) 
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4.3 Representativeness of Sample 
 To assess the representativeness of the sample, sex and ARVC clinical status of 
respondents (final sample) for the pilot phase were compared to all participants who met 
inclusion criteria in the study (original sample). Chi-square test results for these analyses 
are presented in Table 4.2. Clinical status was determined to not be representative of the 
original population X2(1, n = 411) =4.15, p < .05. Sex was also not representative of the 
original sample population X2 (1, n = 485) = 14.56, p < .05. 
Table 4.2 Chi-square comparison on clinical status and sex of final sample population and 
original population. 





























206 (49)  
215 (51) 
14.56 1 
*p = 0.042 
** p = 0.000 
4.4 Scale development and validation 
The results of the scale development and validation are based on the pilot testing 
of the survey instrument, and should be interpreted as preliminary. Mean scale scores 
were used in the data analysis methods to minimize the effect of missing data. 
4.4.1 Construction of Hypothesized subscales 
Five hypothesized subscales comprising the Perceived Economic Burden (PEB) of 
ARVC scale were constructed using original survey items on the basis of face validity, 
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content validity and the literature. Seven original survey items were determined to not 
contribute to face validity and were excluded from the hypothesized scales. The 
remaining 62 survey items were divided into their respective hypothesized subscales as 
follows: Human Capital Scale (12 items); Labour Supply and Productivity scale (29 
items); Consumption and Savings scale (9 items); Financial Burden Scale (8 items); 
Insurance scale (4 items). Seven binomial survey items were also included in the original 
survey tool and although not included in the hypothesized subscales were retained as 
independent descriptive items. The classification of original survey items into their 
respective subscales is presented in Table F1 in Appendix F. 
4.4.2 Item Level and Subscale Descriptive Statistic Analysis 
 Table F2 in Appendix F displays descriptive statistics for each survey item. Mean 
scores on items ranged from 1.48 (SD 0.75) to 4.11 (SD1.18). The majority of items had 
mean scores less than 3 with missing values ranging from 0% to 13.6%. All items 
minimum and maximum values for response values were 1 to 5 for ordinal survey items 
and 1 to 0 for binary (Y/N) survey items. All response choices were used for the majority 
items (94.7%); however, four items indicated 0 responses for a particular choice (Indir11, 
Indir12, Indirofm6, Income8).   
 Items included in hypothesized subscales were examined to determine if the 
means were roughly equivalent for all scale items and that standard deviations were 
roughly equivalent and around 1.0 (Ware & Gandek, 1998). These results are presented in 
Table F3 in Appendix F. All item means within their respective scale are roughly 
equivalent with ranges from 1.81 – 3.03 for HC, 1.48 – 3.08 for LSP, 2.10-3.03 for CS, 
1.98-2.78 FB, 2.70-3.94 for IN. Standard deviations are also roughly the same for all 
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items within subscales and around 1.0: HC (1.01 – 1.54), LSP (0.74 – 1.65), CS (1.20 – 
1.52), FB (1.14 – 1.48), IN (1.25 – 1.37). 
4.4.3 Scale Level Assumptions 
Validity of the hypothesized subscales was tested using scale level assumptions 
for Likert scaling indicated by Ware & Gandek (1998). The multitrait/multiitem 
correlation matrix used for these analyses are presented in Table F3 in Appendix F.  
The first assumption tested was for item internal consistency. Results 
demonstrated that all items’ correlation coefficients with their respective scales are larger 
than 0.40 (range 0.41 to 0.86), which indicates a substantial and satisfactory item internal 
consistency (Ware & Gandek, 1998). The second assumption tested was for equality of 
item-scale correlations. Results indicated that the individual items comprising the scales 
contributed roughly equal proportions of information to their respective total scale score; 
HC scale range 0.66 – 0.84; LSP scale range 0.41- 0.77; CS scale range 0.62-0.85; FB 
scale range 0.70 – 0.86; and IN scale range 0.56 – 0.85. Ware & Gandek (1998) indicate 
that it is satisfactory for item-scale correlations to vary (e.g., from 0.40 to 0.70,) across 
the same scales, and therefore the scales appear to satisfy the assumption for equality of 
item-scale correlation.  
The final assumption tested used item discriminant validity to determine the 
extent to which an item measured concepts outside of its hypothesized subscale in the 
competing subscales. Item discriminant validity was supported if the correlation of an 
item with its hypothesized scale is significantly higher than with other scales; significance 
level was equal to 2 standard errors (approximately a 95% confidence interval) (Ware & 
Gandek, 1998). A total of 244 item discriminant tests were completed determined by the 
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number of items in each scale multiplied by the number of scales in the matrix minus 1. A 
summary of possible test results is presented in Table 4.3.  
Table 4.3 Possible test results for item discriminant validity tests 
Test Result 
Value 
Result Item Discriminant 
Validity Supported 
+2 Correlation significantly greater for 
hypothesized scale compared to 
competing scale 
Yes 
+1 Correlation greater, but not 
significantly, for hypothesized scale 
compared to competing scale 
Yes (on preliminary basis) 
-1 Correlation lower, but not 
significantly, for hypothesized scale 
compared to competing scale 
No 
-2 Correlation significantly lower for 




Item discriminant validity test are presented in Table F4 in Appendix F. The 
majority of the 244 tests indicated that item discriminant validity was supported with test 
result values of +2 and +1. Three items failed the test for discriminant validity (LSP6, 
LSP7, CS3) all receiving a test value of -1 for one of the competing scales. Items that 
failed tests for discriminant validity were retained in the scales as their correlations were 
not significantly lower and items were determined to contribute content validity to their 
respective scales. Ware & Gandek suggest that failure of item discriminant validity tests 
may result in less efficient scales and recommend translation of these items for future 
studies. As this study represents initial validation work, they were retained for their 
descriptive value and as a basis for translation in future work.  
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4.4.4 Reliability of Proposed Subscales 
 Descriptive statistics for the five subscale mean scores are presented in Table 4.4. 
For each respondent, the mean score for each subscale was calculated and used for the 
analysis. The mean scale scores of respondents for all five subscales ranged from a 
minimum of 1.00 to a maximum of 5.00. The means for the mean scores ranged from 
2.07 (SD 0.83) for the LSP subscale to 3.45 (SD 1.08) for the IN subscale. 
Table 4.4 Descriptive statistics for subscale means scores. 
Scale Mean SD Minimum Maximum 
HC 2.43 1.07 1.00 5.00 
LSP 2.07 0.83 1.00 5.00 
CS 2.40 1.02 1.00 5.00 
FB 2.28 1.03 1.00 5.00 
IN 3.45 1.08 1.00 5.00 
  
 Cronbach’s alpha (reliability) coefficients for each subscale were calculated to 
determine internal consistency. The reliability coefficients for the five subscales ranged 
from 0.75 for IN to 0.94 for LSP with values of 0.90, 0.91 and 0.93 for the CS, FB and 
HC scales. All of the reliability coefficients were above the minimum acceptable level of 
0.70 suggested for group level comparisons (Nunnally & Bernstein, 1994). Therefore all 
five subscales were found to have good internal consistency and were considered reliable. 
4.4.5 Validity of Perceived Economic Burden Scale 
The overall perceived economic burden (PEB) of ARVC scale was analyzed to 
determine whether each of the five subscales were making distinct and unique 
contributions to the overall scale. Reliability coefficients for each subscale were 
compared with Pearson correlations for each competing subscale: results are presented in 
Table 4.5. 
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Table 4.5 Reliability coefficients and inter-scale correlations 
Scale HC LSP CS FB IN 
HC (0.94)  
LSP 0.61 (0.94)  
CS 0.55 0.64 (0.90)   
FB 0.53 0.70 0.91 (0.91)  
IN 0.53 0.47 0.39 0.35 (0.75) 
*Scale reliability coefficients (Chronbach’s alpha coefficient) presented on the 
diagonal 
 
The alpha coefficients for four out of the five subscales were larger than the correlation 
coefficients indicating that there is unique reliable variance measured by each of these 
subscales (Ware & Gandek, 1998). The alpha coefficient for the FB scale was the same as 
its correlation coefficient with the CS, indicating that these scales may be performing like 
alternate measures of similar concepts. The final constructed and preliminary validated 
PEB scale survey tool is displayed in Appendix H. 
4.5 Empirical Results: Predictors of Perceived Economic Burden 
4.5.1 Human Capital Attainment 
4.5.1.1 HC Regression Analysis 
Multiple regression analysis was conducted to examine the relationship between 
HC scale scores and various other possible predictors (n = 64). Normality Probability Plot 
of Regression Standardized Residuals and Scatterplot are presented in Appendix G. 
Preliminary analysis of the regression Normal Probability Plot / scatterplot indicated that 
no violation of normality, linearity, and homoscedasticity assumptions had occurred. 
Additionally, tests for multicollinearity indicated no violation with all tolerance levels> 
0.10 (0.33 – 0.89) and Variance Inflation Factor (VIF) scores < 10 (1.1 – 4.2).  
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Model summary result SPSS® outputs are presented in Figure 4.1. The 
coefficients affectedmale, affectedfemale, unaffected female, edupostsecondary, age, 
haschildren and unemployed_retired entered in the model accounted for 17.5% of the 
variance (R square 0.175) in HC scale scores F (8,55) = 1.46, p > .05.  
 
Figure 4.1 SPSS® Multiple Regression Model Output HC scale. 
Model coefficient SPSS® outputs are presented in Table 4.6. Examination of the 
regression coefficient revealed a single statistically significant coefficient, affectedmales, 
B = 1.23 (SE 0.61), p < .05. This result indicates that after controlling for other predictors 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
1 .419a .175 .055 1.02440 
a. Predictors: (Constant), missing_dem, affectedfemale, haschildren, age, 
edupostsecondary, affectedmale, unemployed_retired, unaffectedfemale 







Square F Sig. 
1 Regression 12.278 8 1.535 1.463 .192b 
Residual 57.717 55 1.049   
Total 69.995 63    
a. Dependent Variable: HC 
b. Predictors: (Constant), missing_dem, affectedfemale, haschildren, age, 
edupostsecondary, affectedmale, unemployed_retired, unaffectedfemale 
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in the model, affected males reported higher perceived HC scale scores. All other 
predictor variables were not statistically significant predictors of HC scale scores.  
 
Table 4.6 Regression coefficients output summary for HC scale. 
Coefficient Reference Category B SE t p 
Affected Males Unaffected Males 1.23 0.61 2.02     .048 
Affected Females Unaffected Males 0.49 0.53 0.92 .362 
Unaffected Females Unaffected Males 0.18 0.52 0.35 .727 
Some or Completed 
Post Secondary 
Education 
Some High School (HS) 
or HS Diploma 
0.10 0.32 0.32 .752 
Age N/A - 0.01 0.01 - 0.71 .487 
Has Children N/A 0.45 0.37 1.22 .228 
Unemployed or 
Retired 
Employed 0.30 0.35 0.09 .932 
* Missing demographic information was controlled for by inclusion of a missing 
demographic variable in the regression model (data not shown).  
 
4.5.2 Labour Supply and Productivity Results 
4.5.2.1 LSP Regression Results 
Multiple linear regression was conducted to examine the relationship between 
LSP scale scores and various potential predictors (n = 64). Normality Probability Plot of 
Regression Standardized Residuals and Scatterplot are presented in in Appendix G. Test 
for multicollinearity indicated no violation of this assumption with all tolerance levels > 
0.10 (0.23 – 0.71) and VIF scores < 10 (1.3 – 4.3). Inspection of the regression Normal 
Probability plot and scatterplot indicated no violations for normality, linearity, 
multicollinearity and homoscedasticity assumptions.  
Model summary SPSS® output results are displayed in Figure 4.2. The 
coefficients affectedmale, affected female, unaffectedfemale, age, haschildren, 
incomegreater50, married_livingwithpartner and missing_dem entered accounted for 
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18.5% of variance (R square 0.185) in LSP scores F (9,54) = 1.36, p = > .05.  
Examination of the regression coefficients presented in Table 4.7 revealed no significant 
predictors for LSP scale scores.  
 













Model R R Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
1 .430a .185 .049 .80643 
a. Predictors: (Constant), missing_dem, affectedfemale, haschildren, age, 
married_livingwithpartner, incomegreater50, affectedmale, 
unemployed_retired, unaffectedfemale 








Square F Sig. 
1 Regression 7.955 9 .884 1.359 .230b 
Residual 35.118 54 .650   
Total 43.073 63    
a. Dependent Variable: LSP 
b. Predictors: (Constant), missing_dem, affectedfemale, haschildren, age, 
married_livingwith, incomegreater50, affectedmale, unemployed_retired, 
unaffectedfemale 
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Table 4.7 Regression coefficients output summary for LSP scale. 
Coefficient Reference Category B SE t p 
Affected Males Unaffected Males 0.84 0.49 1.70 .096 
Affected Females Unaffected Males 0.26 0.42 0.54 .535 
Unaffected Females Unaffected Males - 0.05 0.42 - 0.12 .906 
Age N/A 0.03 0.01 0.23 .816 
Unemployed or 
Retired 
Employed - 0.14 0.28 - 0.50 .617 
Income > $50,000 Income < $50,000 - 0.22 0.25 -0.89 .377 
Married or Living 
With a Partner 
Single or Divorced 0.27 0.29 0.93 .358 
Has Children N/A 0.22 0.30 0.73 .469 
* Missing demographic information was controlled for by inclusion of a missing 
demographic variable in the regression model (data not shown).  
 
4.5.2.2 Chi-square LSP analysis 
A chi-squared test for independence was performed to determine the relationship 
between sex/clinical status and binomial survey item responses Indir13 (unable to work 
due to own risk), Indir14 (short-term disability), Indir15 (long-term disability), Indir16 
(unable to work due to other family member’s risk), Indof8 (family member unable to 
work due to respondent’s risk). No significant relationship was observed for LSP items 
Indir13, Indir16 and Indof8. Table 4.8 presents the results for the chi-square model for 
items Indir14 and Indir15. 
 The relationship between going on short-term disability (Indir14) and the clinical 
status/sex variables was significant, X2 (3, n = 62) = 16.64, p <.05 with a large effect size 
Cramer’s V = 0.52. Affected males were more likely to report having to go on short-term 
disability as a result of their risk for ARVC than were unaffected males, affected females, 
and unaffected females. Similarly, the relationship between going on long-term disability 
(Indir15) and the clinical status/sex variables was significant, X2 (3, n = 62) = 10.75, p < 
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.05 with a moderate effect size (Cramer’s V = 0.42). Affected males were more likely to 
report having to go on long-term disability as a result of their risk for ARVC than were 
unaffected males, affected females, and unaffected females. 
Table 4.8 Chi-square model summary for binomial items Indir14 and Indir15. 








Total X2 df 





Yes 4 0 1 0 5 













10 5 27 20 62 





Yes 2 0 0 0 2 













10 5 27 20 62 
* p = .001 
** p = .013 
 
4.5.3 Consumption and Savings Results 
4.5.3.1 CS Regression Results 
Multiple linear regression was performed to examine the relationship between CS 
scale scores and various possible predictors (n = 62). Multicollinearity assumption tests 
indicated no violation with all tolerance levels > 0.10 (0.26 – 0.89) and VIF scores < 10 
(1.2 – 3.9). Normality Probability Plot of Regression Standardized Residuals and 
Scatterplot are presented in Appendix G. Visual inspection of the regression Normal 
Probability plot and scatterplot indicated no violations for normality, linearity, and 
homoscedasticity assumptions.  
Figure 4.3 present the SPSS® model summary output for the CS regression 
analysis. The coefficients missing_dem, affectedfemale, haschildren, eduuptoHS, 
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unemployed_retired, affectedmale, incomegreater50, unaffectedfemale entered accounted 
for 25% of variance (R square 0.250) in CS scores, F (8,53)= 2.21, p < .05.  
 
Figure 4.3 SPSS® regression model output for CS scale. 
 
Model coefficients are presented in Table 4.9. The affectedmales coefficient was a 
significant predictor for CS scale scores B =1.49 (SE 0.54), p < .05. These results indicate 
that after controlling for other predictors in the model, affected males reported higher 
consumption and savings perceived burdens. It should be noted that the affectedfemale 
coefficient is significant at a 10% level of significance B =0.88, (SE 0.48), p < .1. All 







Std. Error of 
the Estimate 
1 .500a .250 .137 .94329 
a. Predictors: (Constant), missing_dem, affectedfemale, haschildren, 
eduuptoHS, unemployed_retired, affectedmale, incomegreater50, 
unaffectedfemale 








Square F Sig. 
1 Regression 15.724 8 1.966 2.209 .041b 
Residual 47.160 53 .890   
Total 62.884 61    
a. Dependent Variable: CS 
b. Predictors: (Constant), missing_dem, affectedfemale, haschildren, 
eduuptoHS, unemployed_retired, affectedmale, incomegreater50, 
unaffectedfemale 	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Table 4.9 Regression coefficients output summary for CS scale. 
Coefficient Reference Category B SE t p 
Affected Males Unaffected Males 1.49    0.54 2.76 .008 
Affected Females Unaffected Males 0.88    0.48 1.82 .071 
Unaffected Females Unaffected Males 0.23    0.50 0.46 .651 
Has Children N/A 0.23    0.35 0.67 .506 
Income > $50,000 Income < $50,000 - 0.51    0.33 - 1.54 .128 
Unemployed or 
Retired 
Employed - 0.08    0.27 - 0.31 .759 
Some High School 
(HS) or HS Diploma 
Some or Completed Post 
Secondary Education 
- 0.45    0.35 - 1.30 .201 
* Missing demographic information was controlled for by inclusion of a missing 
demographic variable in the regression model (data not shown).  
 
4.5.4 Financial Burden 
4.5.4.1 FB Regression Results 
Multiple regression analysis was conducted to examine the relationship between 
FB scale scores and various potential predictors (n = 62). Results revealed that no 
violations for multicollinearity assumptions occurred as all tolerance levels were > 0.10 
(0.23 – 0.71) and VIF scores < 10 (1.3 – 4.3). Normality Probability Plot of Regression 
Standardized Residuals and Scatterplot are presented in Appendix G. Interpretation of the 
Normal Probability plot /scatterplot for the regression revealed no violations for 
normality, linearity, and homoscedasticity assumptions.  
Results for the model summary are presented in Figure 4.4. The coefficients 
missing_dem, affectedfemale, haschildren, age, incomegreater50, affectedmale, 
unemployed_retired, unaffectedfemale entered accounted for 24.3% of variance (R square 
= 0.243) in FB scale scores, F (8,53) = 2.13, p < .05.  
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Figure 4.4 SPSS® regression model output for FB scale. 
Model coefficients are presented in Table 4.10. Two coefficients were significant 
predictors for FB scale scores; affectedmales B = 1.84 (SE 0.57), p < .05; affectedfemales 
B = 1.28 (SE 0.50), p < .05. These results indicate that after controlling for other variables 
in the model, both affected males and affected females score higher on perceived FB 
scale scores. All other predictor variables were not statistically significant predictors for 










Model R R Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
1 .493a .243 .129 .95817 
a. Predictors: (Constant), missing_dem, affectedfemale, haschildren, age, 
incomegreater50, affectedmale, unemployed_retired, unaffectedfemale 







Square F Sig. 
1 Regression 15.643 8 1.955 2.130 .049b 
Residual 48.658 53 .918   
Total 64.302 61    
a. Dependent Variable: FB 
b. Predictors: (Constant), missing_dem, affectedfemale, haschildren, age, 
incomegreater50, affectedmale, unemployed_retired, unaffectedfemale 	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Table 4.10 Regression coefficients output summary for FB scale. 
Coefficient Reference Category B SE t p 
Affected Males Unaffected Males 1.84 0.57 3.20 .002 
Affected Females Unaffected Males 1.28 0.50 2.56 .013 
Unaffected Females Unaffected Males 0.55 0.50 1.08 .284 
Has Children N/A 0.36 0.36 1.01 .318 
Unemployed or 
Retired 
Employed - 0.47 0.35 - 1.32 .192 
Income > $50,000 Income < $50,000 - 0.21 0.29 - 0.73 .466 
Age N/A 0.02 0.01 1.37 .177 
* Missing demographic information was controlled for by inclusion of a missing 
demographic variable in the regression model (data not shown).  
 
4.5.5 Insurance Results 
4.5.5.1 IN Regression Analysis 
 Multiple linear regression was conducted to examine the relationship between IN 
scale scores and various potential predictors (n = 61). No violation of multicollinearty 
occurred with all tolerance levels > 0.10 and VIF scores <10. Normality Probability Plot 
of Regression Standardized Residuals and Scatterplot are presented in Appendix G. 
Normal Probability Plot and scatterplot analysis indicated no violations for normality, 
linearity or homoscedasticity assumptions.  
Model summary results are reported in Figure 4.5. The coefficients 
single_divorce, incomegreater50, affectedfemale, unemployed_retired, 
edunpostsecondary, haschildren, affectedmale, missing_dem, age, unaffectedfemale 
entered accounted for 30% of variance (R square 0.30) in IN scale scores, F (10,50) = 
2.14, p < .05. 
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Figure 4.5 SPSS® regression model output for IN scale. 
 
Model coefficients are presented in Table 4.11. Two coefficient were significant 
predictors for IN scale scores:  affectedmales B = 1.64 (SE 0.66), p < .05, and 
educationpostsecondary B = 0.87 (SE 0.37), p < .05. These results indicate that after 
controlling for other predictors, both affected males and those with some or completed 
post-secondary education report higher IN scale scores. It should be noted that the 
affectedfemales coefficient was significant at 10%, B = 1.12 (SE 0.6), p < .1. All other 








Std. Error of 
the Estimate 
1 .547a .299 .159 .94731 
a. Predictors: (Constant), single_divorce, incomegreater50, 
affectedfemale, unemployed_retired, edunpostsecondary, 
haschildren, affectedmale, missing_dem, age, unaffectedfemale 








Square F Sig. 
1 Regression 19.169 10 1.917 2.136 .039b 
Residual 44.870 50 .897   
Total 64.039 60    
a. Dependent Variable: IN 
b. Predictors: (Constant), single_divorce, incomegreater50, affectedfemale, 
unemployed_retired, edunpostsecondary, haschildren, affectedmale, 
missing_dem, age, unaffectedfemale 	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Table 4.11 Regression coefficients output summary for IN scale. 
Coefficient Reference Category B SE t p 
Affected Males Unaffected Males 1.64 0.66 2.49 .016 
Affected Females Unaffected Males 1.12 0.60 1.87 .067 
Unaffected Females Unaffected Males 0.60 0.61 0.99 .328 
Has Children N/A 0.58 0.36 1.60 .117 
Unemployed or 
Retired 
Employed - 0.39 0.36 - 1.08 .285 
Income > $50,000 Income < $50,000 - 0.35 0.35 - 1.00 .323 
Age N/A 0.00 0.01 0.07 .943 
Some or Completed 
Post Secondary 
Education 
Some High School 
(HS) or HS Diploma 
0.87 0.37 2.35 .023 
Single or Divorced Married or Living 
With a Partner 
- 0.10 0.38 -0.27 .791 
* Missing demographic information was controlled for by inclusion of a missing 
demographic variable in the regression model (data not shown).  
 
4.5.5.2 Chi-square IN analysis 
A chi-squared test for independence was performed to determine the relationship 
between sex/clinical status and binomial survey item responses Insur7 (payment of higher 
premiums for medical insurance) and Insur8 (denial of medical insurance). No significant 
relationship was observed for Insur8. Table 4.12 presents results for the chi square model 
for item Insur7. The relationship between paying higher premiums for medical insurance 
and the clinical status/sex variables was significant, X2 (3, n = 61) = 13.02, p < .05 with a 
moderate effect size Cramer’s V = 0.46. Affected males were more likely to report to 
perceive paying higher insurance premiums as a result of their risk for ARVC than were 
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Table 4.12 Chi-square model summary for binomial item Insur7. 





















4 5 17 18 44 
 
10 5 27 19 61 
* p = .005 
4.6 Summary 
Overall, the results section demonstrates the final characteristics of the sample 
population, the construction of the PEB scale, its validation, and the use of multiple linear 
regression and chi-square analysis in an attempt to explain some of the data collected 
from the sample. A brief summary of the results section is presented below. 
A final sample of n = 64 was obtained from the data collection timeframe of 
December 1, 2013 to May 30, 2014 as indicated in section 4.1 of this chapter. The sample 
was determined to not be representative of the population for clinical status 
(affected/unaffected) nor for sex (section 4.3). Approximately 60% of the sample were 
affected and the majority of the respondents were female (77%). 
 The Perceived Economic Burden scale was constructed to be composed of five 
subscales22 and was analyzed for both validity and reliability according to previous work 
by Ware & Gandek (1998) in the second section of this chapter (Section 4.4). All items 
within the five hypothesized subscales had roughly equivalent means and standard 
deviation of approximately 1.0. Furthermore, tests for Likert scale assumptions for item 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
22 Human Capital Scale (HC); Labour Supply and Productivity scale (LSP); Consumption and Savings scale 
(CS); Financial Burden Scale (FB); Insurance scale (IN) 
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internal consistency and equality of item-scale correlation achieved satisfactory results. 
The final test for the item discriminant validity assumption achieved satisfactory results 
for all but three items, which were not removed from their subscales due to their content 
validity and the pilot nature of this work. All reliability coefficients (Cronbach’s alpha) 
were above the minimal acceptable range of 0.70 indicating that all five subscales had 
good internal consistency and are considered reliable (Table 4.5). The final step in the 
validation process indicated that three of the five subscales were making unique 
contributions to the overall PEB scale with results indicating that the FB and CS scales 
may be performing like alternate measures of similar concepts. 
 Section 4.5 of this chapter presented the empirical analysis of the data. Multiple 
linear regression analysis was conducted on all five subscales to determine the effect of 
clinical status and sex and other demographic characteristics on the various perceived 
burden areas. Regression analysis indicated that affected males perceived significantly 
greater levels of burden in human capital, consumption and savings, financial burden and 
insurance. Affected females also reported statistically significant increased perceived 
burden with respect to financial burden and were significant predictors of consumption 
and savings and insurance at 10%. Finally, those with some or completed post secondary 
education also perceived greater insurance burden than those with lower levels of 
education.  
Chi-square analysis was used to determine the relationship between responses to 
binomial questions and clinical status/sex categories. These results indicated that affected 
males reported having to go on both short-term and long term-disability compared to 
unaffected males, affected females and unaffected females. A similar result was observed 
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in a question about insurance where affected males perceived paying higher premiums 
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Chapter 5: Discussion 
 This study had three main empirical components; the development of a survey 
tool, the initial validation of the Perceived Economic Burden (PEB) of ARVC scale, and 
the application of the PEB scale to examine the perceived economic burden experienced 
by families with a known family/genetic history of ARVC caused by the p.S538L 
mutation in TMEM43. Similarly, the study aimed to determine the influence of various 
demographic and clinical characteristics on the perceived economic burden such as 
clinical status, sex, age, having children, education level, employment status income and 
marital status. To date, this appears to be the first quantitative study to explore the 
perceived economic burden in this population. Few studies exist that examine how 
individuals and families with serious genetic conditions alter their career, education and 
savings plan choices based on their genetic diagnosis. Previous preliminary qualitative 
research on this population by members of our research team has indicated perceived 
economic burden in areas such as employment abilities and choices, worry about 
insurance for self and children, decreased household spending, and the need for childhood 
employment (Etchegary et al., 2015).  
5.1 Survey Response Rates and Representativeness of The Sample  
The response rate for this study was 37.2%. Approximately 77% of respondents 
were female. Fewer males in the final sample appear to explain the lack of 
representativeness of the sample compared to the population in regards to sex as shown 
by chi-squared analysis. This observation is of particular interest as a higher response rate 
for males was expected due to the sex influence of the disease, affecting males more 
severely than females. Female respondents often dominate survey research, including 
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health research, and the current study was no different (Mindell et al., 2015; Moore & 
Tarnai, 2002). Future research efforts to recruit males would be valuable given the sex 
influence of ARVC. Similarly, unaffected individuals were under represented in the 
sample comprising 41% of the sample. It is possible that the unaffected population were 
less likely to respond as they did not perceive any economic burden according to their 
risk and felt the study was not applicable to them.  
5.2 Perceived Economic Burden (PEB) Scale Construct and Validation 
 The first two objectives of this study were to develop, construct and validate an 
instrument to measure the perceived economic burden of ARVC caused by the p.S538L 
mutation in TMEM43. The initial economic impact of ARVC survey instrument was 
developed resulting in the subsequent construction of the PEB scale as a tool to 
quantitatively measure the perceived economic burden of living with a family and genetic 
history of ARVC. Both qualitative study findings on the economic burden experienced by 
ARVC families and supplemental literature discussing the economic burden experienced 
due to illness and diseases were used to develop the original 76 survey items. Utilizing 
available data from a the previous qualitative study on the population was particularly 
advantageous to this study as the content was reflective of personal experiences within 
the ARVC population and it contributed to the face and content validity of the scale. 
Gilgun (2004) supports the combination of qualitative research with literature reviews in 
scale construction as this method provides confidence in scale content and increases face 
validity of concepts that comprise scales.  
 This study provides preliminary evidence supporting the psychometric properties 
of the PEB scale. The findings from the Multitrait/Multi-Item analysis validation suggest 
	   89 
that the PEB scale (including each of the 5 subscales) met Likert scaling assumptions 
(Ware & Gandek, 1998). When applied to findings from the ARVC sample, the PEB 
scale had satisfactory item internal consistency, equality of item-scale correlations, and 
discriminant validity for most items. Scale items that did not support item-discriminant 
validity are retained in the current version of the scale on the basis of their contribution to 
content validity, their minimal impact on validity and the exploratory nature of this study. 
PEB scale validation findings provided evidence to support its validity, where each of the 
subscales contained relevant content and measured their desired properties. This 
validation provides preliminary confirmation that PEB scale scores are appropriate, 
meaningful and useful and therefore inferences and claims made from scale scores can be 
interpreted with a higher degree of confidence (Zumbo & Chan, 2014). Reliability testing 
using Chronbach’s alpha coefficients for all five subscales provided good internal 
consistency and as a result were determined to be reliable. As such, each subscale likely 
gave consistent accurate results that reflected the true scale score and not random error 
(Ware & Gandek, 1998).  
An important contribution of this study to the economic burden of disease 
research is it provides confirmation of the content validity of measures of economic 
burden. A lack of concrete quantitative measures of economic burden in the literature 
required that this study be exploratory, using a broad scope of subscale and item content. 
The pattern of correlations between subscales is relevant to the content validity of scales 
(Ware & Gandek, 1998). Inter-scale correlation findings demonstrate that the content of 
the subscales are inter-related, yet distinct, and consequently have relevant content 
validity.  
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With the exception of the FB and CS subscales, inter-scale correlation analysis 
found that all other subscales were making a distinct contribution to the overall PEB 
scale. Initially, the FB and CS items were included in the same subscale, however, for 
face validity they were separated as measures of distinct concepts. Additionally, the 
separation of these two concepts contributed to an increase in statistical significance of 
the regression analysis of the ARVC sample data. Despite the inter-scale correlation 
between the FB and CS subscales, the content of each subscale are distinct and therefore 
not likely to be alternate measures of similar concepts. These findings may reflect the 
potential relationship between perceived financial and consumption and savings burdens, 
an area for potential future research. It is expected that future studies with a larger sample 
size would provide additional validation of the PEB scale. 
5.3 Predictors of Perceived Burden  
 The purpose of the empirical analysis of the PEB subscales focuses on identifying 
general trends in the measures of economic burden as opposed to specific scale item 
content. Empirical analysis results represent objective three of the study, of using the 
validated PEB scale to identify predictors of perceived economic burden. These results 
reflect the exploratory nature of this study and provide trends to support future research 
on the economic burden experienced by ARVC families, and to report similar findings 
reflected in the current literature. The findings from multiple regression analysis on the 
five subscale scores suggest differences in perceived burden observed in factors such as 
sex and clinical status.  
The first and most evident difference was observed between affected males and 
females. Affected males perceived higher levels of burden with observed statistical 
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significance in human capital, consumption and savings, financial burden and insurance. 
Affected females only reported statistically significant increased perceived burden with 
respect to financial burden. The results do suggest, however, that affected females 
reported increased perceived burden for consumption and savings and insurance at a 10% 
statistical significance level, and therefore it is likely that with a large sample size these 
measures would be significant. 
Despite the lack of evidence from existing literature that support the observed 
difference between males and females, a possible theory can be hypothesized from what 
is known about ARVC caused by a p.S538L mutation in TMEM43. Factors such as earlier 
symptoms, increased disease severity and shorter life expectancies in males compared to 
females with this subtype of ARVC (Hodgkinson et al., 2013) may contribute to their 
increased perceived burden in the majority of measures. This study therefore suggests that 
affected males experience an increased perceived burden in significantly more of the 
predictors of economic burden compared to affected females. Although it does appear the 
perceived economic burden for affected females is also increased due to ARVC. 
In addition to the overarching sex differences in scale scores discussed above, a 
further exploration of the measures of perceived burden suggests other contributing 
factors as reflected in current literature. The HC scale is intended to capture the 
perceptions of individuals and their families regarding education and career choices as 
they relate to a risk for ARVC. As previously mentioned, regression analysis suggests 
that affected males report a greater perceived HC burden. The observed perceived HC 
burden in this study is supported by previous research on ARVC and other genetic 
conditions (Etchegary et al., 2015; Oster et al., 2013a).  
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ARVC caused by a p.S538L in TMEM43 is associated with physical and safety 
limitations for lifestyle and employment considerations due to disease characteristics and 
treatment with ICDs in addition to a known reduced life expectancy. Therefore affected 
individuals are faced with the challenge of carefully considering their careers, and by 
extension the type and level of education they pursue. One of the main findings from the 
qualitative economic burden evaluation on this population supports considerations for 
future and current employment for ARVC patients, as there were limitations on the type 
of employment that could be safely undertaken (Etchegary et al, 2015). Teachman (2012) 
found that the likelihood of post-secondary enrollment increases by approximately 15% 
when limitation on the type of future work occurred due to disease.  
Contrary to Teachman (2012), a positive genetic test for Huntington disease 
patients and a decreased life expectancy had a negative impact on the level of education 
attained, where affected patients completed less education and were 30% less likely to 
complete post secondary education (Oster et al., 2013a). The greater perceived economic 
burden reported in this study confirms that considerations of education and employment 
are occurring in the ARVC population, particularly for affected men. Although our study 
only measured whether considerations about education and career were occurring, the 
literature supports that decisions can both positively and negatively affect the pursuit of 
higher education, and likely influencing career choices. This presents an important area 
for the clinical management and guidance of ARVC patients in regards to education and 
career choices as our study findings and the literature reflect these choices occurring as a 
result of disease characteristics of ARVC. 
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No significant predictors were observed in the regression model for the labour 
supply and productivity (LSP) scale that measures the perceived burden with respect to 
employment, hours worked, wages, workforce participation and decisions about 
retirement. These results contradict the proportion of literature that suggests 
disease/illness has an impact on hours worked, wages and early retirement (Pelkowski & 
Berger, 2004; Yen et al., 2011). In fact, previous qualitative work suggested that ARVC 
patients and families reported experiences of taking time off work, lessened quality of 
work, or other family members returning to work/working additional hours to make up 
for lost income (Etchegary et al., 2015). A possible protective factor of LSP burden may 
be explained by findings from Etchegary et al. (2015) where participants discussed the 
positive impact of supportive and understanding employers.  
Statistical significance was observed, however, with chi-squared analysis of some 
binomial LSP survey items. Affected males were more likely to report having to go on 
both short-term and long-term disability when compared to affected females, unaffected 
males and unaffected females. These results are consistent with Johansen (1999) who 
concluded that a significant proportion of heart disease patients report being on disability. 
Generally, LSP findings suggest that although employment is affected, the effect of 
ARVC appears to result in short/long term disability rather than a decrease in hours or 
wages. Again, these results demonstrate the possible effect of disease burden for affected 
men, where their disease and implantation of an ICD may be severe enough that affected 
men require extended time off work without leaving the workforce permanently. These 
are important psychosocial issues to be explored in genetic counseling sessions and may 
suggest areas for follow up supportive care and management.  
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The consumption and savings (CS) scale is intended to capture how people make 
decisions about their savings/spending habits and incurred costs associated with their risk 
for ARVC. Results from the multiple regression analysis suggest affected males were the 
single statistically significant predictor of CS scale scores being more likely to report 
perceived burden. These results support the notion of precautionary saving in response to 
future health uncertainty and a risk of poor health reflected in the literature (Japelli et al, 
2007; Palumbo, 1999). Furthermore, the study results also suggest that affected male 
ARVC patients and their families incur costs associated with medications, travel for 
medical appointments and other costs as a result of their risk for ARVC, consistent with 
the broader literature on chronic disease management (McGillion et al., 2008; Sanmartin 
et al., 2014).  
Out-of-pocket costs for health related expenses were an expected finding from this 
study as research suggests these costs are increasing for Canadians (Sanmartin et al, 
2014), and patients with heart disease have reported significant out-of-pocket costs 
(McGillan et al, 2008). Findings from Etchegary et al. (2015) also support these findings 
with ARVC patients incurring costs associated with treatment and expressing concerns 
over financial planning. It appears that the ARVC population in Newfoundland and 
Labrador makes decisions that reflect anticipatory savings, while incurring medical 
related costs that are not covered by the publically funded health care system.  
Financial burden was measured by the FB subscale capturing the effect of 
contributing factors to financial burden such as the need for regular monitoring, costs of 
medication, costs for travel and other potential costs. Both affected males and affected 
females reported a statistically significant increase in reported perceived financial burden. 
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These finding are expected as affected males also reported an increased perceived burden 
in their spending on health related goods and services and savings decisions that likely 
relate to an increase in financial burden.  
Finally, the insurance (IN) scale intended to capture challenges and concerns with 
existing or obtaining medical or life insurance coverage as a result of a risk for ARVC. 
Two significant predictors of perceived IN burden were observed (i) those with an 
education of some or completed post-secondary education and (ii) affected males. These 
two groups had a higher likelihood of reporting an increasd perceived burden associated 
with insurance coverage. A higher level of education was identified by Bombard et al. 
(2011) as one of the factors that increased the likelihood of genetic discrimination in 
Huntington disease patients. The results from this study support these previous findings in 
a genetic disease population perhaps suggesting that those with higher education levels 
are more likely to purchase additional medical or life insurance.  
A greater perceived IN burden was expected for affected men; however, an 
unexpected finding for the insurance scale was the non-significant predictor of affected 
women. This may again reflect the sex dependence of this subtype of ARVC where 
females experience a wider variety of disease severity, while men experience increased 
disease severity. These findings may be explained by previous research conducted by 
Bombard et al. (2009) where insurance discrimination was found to reflect disease and 
family histories and not necessarily the result of actual genetic testing results. Findings 
suggesting a concern over the ability to obtain insurance are mirrored in the study by 
Etchegary et al. (2015) where having enough insurance was a major worry for 
participants.  
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Sex differences were also observed in the chi-squared analysis of an item intended 
to capture paying a higher premium for private extended health insurance. The 
relationship between paying higher premiums and clinical status suggests a statistically 
significant difference for affected men who were more likely to report the perception of  
paying higher insurance premiums compared to all other clinical status/sex groups. 
Although it was expected that clinical status would be related to perceived insurance 
burden, factors such as 91% of all extended health coverage coming from employee 
benefits packages was expected to be a protective factor against insurance burden 
(Canadian Life and Health Insurance Association, 2013). Employee benefit packages 
were suggested to be a potential protective factor for ARVC patients as good insurance 
plans from employers lessened worries over insurance coverage in qualitative interviews 
(Etchegary et al., 2015). Current study findings may indicate that a significant proportion 
of affected men in the ARVC population may either not be enrolled in extended health 
insurance coverage or their type of employment/employer may not offer group coverage.  
5.4 Study Limitations 
Despite efforts to ensure increased response rates such as facilitating respondent 
preference in survey (electronic or hard copy) methods and follow up calls, a relatively 
small sample size is a limitation of this study. This is particularly reflected in the 
representativeness of the sample where males and unaffected individuals were under 
represented. Therefore the perceived economic burden might well be greater for 
individuals and families where the male was at risk for ARVC or unaffected individuals 
may experience an increased burden, at least in childhood, as qualitative findings seem to 
suggest. Future research with greater number of males and unaffected individuals would 
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be valuable. Additionally, an increase in sample size may provide statistical significance 
for affected females for the consumption and savings and insurance measures. 
Another study limitation was the inability to perform factor analysis as a 
component of scale validation. Additional studies using the PEB scale to evaluate 
economic burden with a larger sample size would allow for factor analysis as a 
component of scale validation and further increase validity of the scale. 
Lastly, although significant differences were identified for the majority of 
subscale measures for economic burden, the magnitude of these differences were not 
discussed in this study. Therefore, although predictors of perceived economic burden 
were identified, the degree to which the difference between predictors such as being an 
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Chapter 6: Conclusion and Future Recommendations 
 This study used findings from the existing literature to develop survey items, 
construct, and validate a scale (PEB scale) to measure the perceived economic burden 
associated with ARVC caused by the p.S358L mutation in TMEM43. The PEB scale was 
then used to explore predictors of perceived economic burden particularly clinical status 
and sex. This study provides important information to allow the provision of adequate 
holistic care, and to inform future policy decisions for programs and services offered to 
ARVC patients. Furthermore, it contributes to the identified gap in the wider literature on 
the economic burden of ARVC and other genetic conditions. 
 Validation of the PEB scale provided preliminary evidence of the psychometric 
properties of the scale allowing results to be interpreted with a greater degree of 
confidence. This process also confirmed the validity of the measures of economic burden 
selected from the literature.  
We found that affected males reported an increased perceived economic burden in 
human capital attainment, consumption and savings, financial burden, and insurance. 
Affected females also reported financial burden as it related to their risk for ARVC. A 
study with a larger sample size is likely to report statistical significance for consumption 
and savings and insurance for affected females. Study findings suggest that affected 
males experience a significantly greater perceived burden across the measures of 
economic burden compared to affected females, and both unaffected groups. Although 
the sample size is small (10 affected males), results suggest affected males report having 
to go on short-and long-term disability and experience paying higher premiums for 
private medical insurance.  
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Findings on HC suggest that affected males make considerations and decisions 
about their education and employment related to their risk for ARVC. Affected males also 
reported increased perceived burdens in the form of precautionary savings in anticipation 
of future health events, and those associated with incurred costs for medications or travel 
for medical appointments as suggested in CS scale results. Financial burden (FB) was 
perceived by both affected males and females as a result of costs incurred related to their 
risk for ARVC. Those with a higher level of education and affected males experienced 
greater perceived burden in obtaining insurance for themselves or their families. 
Our findings suggest the importance of supporting the clinical treatment of ARVC 
patients with counseling or guidance that extends to education and career choices based 
on limitations caused by their condition. Findings also suggest that despite a universal 
health care system in Canada, ARVC patients still experience economic burden, 
particularly associated with costs not covered by public health insurance. These 
challenges extend to insurance as affected individuals are concerned about the ability to 
obtain insurance and pay higher insurance premiums as a result of their risk for ARVC. 
Extended coverage for ARVC patients, their families and other genetic disease 
populations may act to reduce the experienced burden in this population. Furthermore, 
additional analysis and potential changes to insurance provision may be required to 
mitigate challenges in obtaining insurance resulting from a risk for ARVC or other 
genetic diseases.  
Although this study is a major contribution to the gap in literature on the 
economic burden of ARVC and provides a foundational understanding of the perceived 
economic burden in this population, study limitations such as small sample size support 
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the need for further research in this area. Future studies can act to confirm these study 
findings using a larger sample size, and provide additional analysis of the degree of 
perceived burden experience. Analysis of ARVC disease characteristics within the 
affected population that might influence the level of perceived burden such as disease 
severity or treatment types would also be advantageous allowing for a narrower target for 
clinical support. Finally, the PEB instrument can be further applied to other genetic 
conditions and in different geographic settings to measure the perceived economic burden 
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Appendix	  A:	  ARVC	  Task	  Force	  Diagnostic	  Criteria	  (Mckenna et al., 1994; Marcus 
et al., 2010) 	  
1994 Task Force Criteria 2010 Task Force Criteria 
1. Global and/or regional dysfunction and structural alterations 
Major 
 
-Severe dilatation and 
reduction of RV ejection 
fraction with no (or only 
mild) LV impairment 
-Localized RV aneurisms 
(akinetic or dyskinetic areas 
with diastolic bulging) 
-Severe degmental dilation 





By 2D Echo: 
-Regional RV akinesia, dyskinesia, or aneurysm 
and 1 of the following (end diastole): 
• -PLAX RVOT ≥ 32mm (corrected for body size 
[PLAX/BSA] ≥ 19 mm/m2) 
• -PLAX RVOT ≥ 36mm (corrected for body size 
[PLAX/BSA] ≥ 21 mm/m2) 
• or fractional area change ≤ 33% 
 
By MRI: 
- Regional RV akinesia, or dyskinesia or dyssynchronous 
RV contraction and 1 of the following: 
• -Ratio or RV end-diastolic volume to BSA ≥110mL/m2 
(male) or ≥ 100mL/m2 (female) 
• or RV ejection fraction ≤ 40% 
 
By RV angiography: 
-Regional RV akinesia, dyskinesia or aneurysm 
Minor 
 
- Mild global RV dilatation 
and/or ejection fraction 
reduction with normal LV 
-Mild segmental dilation of 
the RV 
-Regional RV hypokinesia 
 
 
By 2D echo: 
-Regional RV akinesia or dyskinesia 
 and 1 of the following (end diastole): 
• -PLAX RVOT ≥29mm to < 32mm (corrected for body 
size [PLAX/BSA] ≥16 to <19 mm/m2) 
• -PLAX RVOT ≥ 32 to <36mm (corrected for body size 
[PLAX/BSA] ≥18 to < 21 mm/m2) 
• or fractional area change > 33% to ≤ 40% 
By MRI: 
- Regional RV akinesia or dyskinesia or dyssynchronous 
RV contraction 
- and 1 of the following: 
• Ratio of RV end-diastolic volume to BSA≥ 100 to < 
110 mL/m2 (male) or ≥90 to 100 mL/m2 (female) 
• or RV ejection fraction >40% to ≤ 45% 
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2. Tissue characterization of walls 
Major 
- Fibrofatty replacement of 
the myocardium on 
endomyocardial biopsy 
 
-Residual mycocytes < 60% by morphometric analysis (or 
< 50% if estimated), with fibrous replacement of the RV 
free wall myocardium in ≥1 sample, with our without fatty 




-Residual mycocytes 60% to 75% by morphometric 
analysis (or 50% to 65% if estimated), with fibrous 
replacement of the RV free wall myocardium in ≥1 sample, 
with our without fatty replacement of tissue on 
endomyocardial biopsy 




- Inverted T waves in right precordial leads (V2 and V3) 
(people age > 12years, in the absence of right-bundle-
branch- block 
Minor 
- Inverted T waves in right 
precordial leads (V1, V2, 
and V3 ) or beyond in 
individuals > 14 years of 
age (in the absence of 
complete right bundle-
branch-block QRS ≥ 120 
ms) 
 
- Inverted T waves leads V1  and V2 in individuals > 14 
years of age (in the absence of complete right bundle-
branch-block) or in V4, V5, or V6. 
- Inverted T waves leads V1   V2, V3, and V4 in individuals 
> 14 years of age in the presence of complete right bundle-
branch-block 
4. Depolarization/conduction Abnormalities 
Major 
- Epsilon waves or localized 
prolongation (>110 ms) of 
the QRS complex in right 
precordial leads (V1 to V3) 
 
- Late potentials (SAECG) 
Minor 
- Epsilon wave 
(reproducible low-
amplitude signals between 
end of QRS complex to 
onset of the T wave) in the 
right precordical leads  (V1 
to V3) 
 
- Late potentials by SAECG in ≥ 1 of 3 parameters in the 
absence of QRS duration of ≥ 110 ms on the standard ECG 
- Filtered QRS duration (fQRS) ≥ 114 ms 
-Duration of terminal QRD <40 µV (low-amplitude signal 
duration) ≥ 38 ms 
- Root-mean-square voltage terminal 40 ms ≤ 20 µV 
- Terminal activation duration of QRS ≥ 55 ms measured 
from the nadir of the S wave to the end of the QRS, 
including R’, in V1, V2, or V3, in the absence of complete 
right bundle-branch block 
5. Arrhythmias 
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Major  
-Left bundle-branch block-type ventricular tachycardia 
(sustained and nonsustained) (ECG, Holter, exercise) 
-Frequent ventricular extrasystoles (>1000 per 24 hours) 
(Holter) 
Minor 
- Nonsustained or sustained 
ventricular tachycardia of 
left bundle-branch 
morphology with superior 
axis (negative or 
indeterminate QRS in leads 
II, III and aVF and positive 
lead aVL) 
 
- Nonsustained or sustained ventricular tachycardia of RV 
outflow configuration, left bundle-branch block 
morphology with inferior axis (positive QRS in leads II, III 
and aVF and negative in lead aVL) or of unknown axis. 
- >500 ventricular extrasystoles per 2 hours (Holter) 
6. Family History 
Major 
- Family disease confirmed 
at necropsy or surgery 
 
- Family history of premature sudden death (<35 years of 
age) due to suspected ARVC/D) 
- Familial History (clinical diagnosis based on present 
criteria) 
Minor 
- ARVC/D confirmed in a 
first-degree relative who 
meets current Task Force 
criteria 
- ARVC/D confirmed 
pathology at autopsy or 
surgery in a first-degree 
relative 
- Identification of a 
pathogenic mutation 
categorized as associated or 
probably associated with 
ARVC/D in the patient 
under evaluation 
 
- History of ARVC/D in a first-degree relative in whom it 
is not possible or practical to determine whether the family 
member meets current Task Force Criteria 
- Premature sudden death (< 35 years of age) due to 
suspected ARVC/D in a first-degree relative 
- ARVC/D confirmed pathologically or by the current Task 
Force criteria in second-degree relative 
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Appendix B: Canada Health Act Principles (Health Canada, 2012b) 
Public Administration:  
 
The provincial and territorial plans must be administered and operated on a non-profit 




The provincial and territorial plans must insure all medically necessary services provided 




The provincial and territorial plans must entitle all insured persons to health insurance 




The provincial and territorial plans must provide all insured persons reasonable access to 




The provincial and territorial plans must cover all insured persons when they move to 
another province or territory within Canada and when they travel abroad. The provinces 
and territories have some limits on coverage for services provided outside Canada, and 
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Appendix C: Original Study Documents 
 
C1: Study Consent Form 
	  	  
Consent	  to	  Take	  Part	  in	  Research	  
  
TITLE: Understanding the psychosocial and economic effects of arrhythmogenic right 
ventricular cardiomyopathy (ARVC) on families in Newfoundland and Labrador	  
   
INVESTIGATOR(S): MSc Candidates: Glenn Enright, Erin Baker 
Research Supervisors: Dr. Rick Audas, Dr. Holly Etchegary, Dr. Kathy Hodgkinson, Dr. 
Daryl Pullman.  
 
SPONSOR: Atlantic Canada Opportunities Agency: Atlantic Innovation Fund 
 
You have been invited to take part in a research study.  Taking part in this study is 
voluntary.  It is up to you to decide whether to be in the study or not.  You can decide not 
to take part in the study.  If you decide to take part, you are free to leave at any time. This 
will not affect your usual health care.  
 
Before you decide, you need to understand what the study is for, what risks you might 
take and what benefits you might receive.  This consent form explains the study.   
 
Please read this carefully. Take as much time as you like. If you like, take it home to think 
about for a while. Mark anything you do not understand, or want explained better. After 
you have read it, please ask questions about anything that is not clear. 
 
The researchers will: 
 
• discuss the study with you 
• answer your questions 
• keep confidential any information which could identify you personally 




Cardiomyopathies are diseases that lead to a weakening of the heart muscle. They are 
genetic diseases that may lead to sudden cardiac death. One such disease is known as 
arrhythmogenic right ventricular cardiomyopathy or ARVC. There are many families in 
Newfoundland (NL) with this condition. We are interested in the effect this condition has 
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on families, including the physical, mental, emotional and economic impacts. We hope 
that by describing psychosocial and economic impacts, we can improve the care we 
provide to at risk families.  
 
 
2.    Purpose of study: 
 
We want to explore the effects of living in a family at risk for sudden cardiac death due to 
ARVC, an inherited heart condition common in NL. If we can better understand how this 
genetic disorder affects people, this should help us improve the care to high risk families.  
 
3.    Description of the study procedures: 
 
You will be invited to take part in completing two surveys lasting about 1 hour total. The 
surveys can be completed wherever you feel most comfortable and will be sent to you in 
the mail, by email or delivered in person. Once you have completed the surveys we would 
kindly ask you to return them in the self-addressed postage paid envelopes or by email. 
There are no right or wrong answers to the questions. We are only interested in your 
thoughts. The surveys will ask questions about your your family’s history of heart 
disease, your thoughts about living at risk for this condition, and the impact the disease 
has had on your life and your family’s life. Your name will never be reported in any 
papers or reports written from the surveys.  
 
4.    Length of time: 
 
You will be expected to fill out two surveys at a place of your convenience. In total, both 
surveys will take about one hour to one hour and a half.  
 
5.    Possible risks and discomforts: 
 
In general, we do not foresee any risks with this study. However, sometimes it can be 
hard to talk about genetic diseases in the family, especially those that can cause young 
death. If you wish, a genetic counsellor will talk about these issues with you. If there are 
still any issues you wish to talk about, referrals can be made for further follow-up.  
 
6.    Benefits: 
 
It is not known whether this study will benefit you.  
 
7.    Liability statement: 
 
Signing this form gives us your consent to be in this study.  It tells us that you understand 
the information about the research study.  When you sign this form, you do not give up 
your legal rights.  Researchers or agencies involved in this research study still have their 
legal and professional responsibilities. 
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8.    What about my privacy and confidentiality?  
 
Protecting your privacy is an important part of this study. Every effort to protect your 
privacy will be made. However it cannot be guaranteed. For example we may be required 
by law to allow access to research records.  
 
        When you sign this consent form you give us permission to  
• Collect information from you 
• Share information with the people conducting the study 
• Share information with the people responsible for protecting your safety        
 
 
Use of your study information 
The research team will collect and use only the information they need for this 
research study.        
 
This information will include your  
• date and place of birth 
• sex 
• family history  
• medical conditions 
• medications 
• the results of tests and procedures you had before and during the study 
• information from study surveys 
 
Your name and contact information will be kept secure by the research team in 
Newfoundland and Labrador.  It will not be shared with others without your 
permission. Your name will not appear in any report or article published as a result 
of this study. 
 
Information collected for this study will be kept for twenty years. If you do not wish 
for the data to be held for this long please select “no” in the correct box below. If you 
select no, your data will be destroyed following this study. 
 
If you decide to withdraw from the study, the information collected up to that time 
will continue to be used by the research team. It may not be removed. This 
information will only be used for the purposes of this study.  
 
Information collected and used by the research team will be stored by Memorial 
University. Dr. Kathy Hodgkinson, the Provincial Medical Genetics program and the 
cardiac care unit are responsible for keeping it secure.  
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Your access to records 
You may ask the study researchers to see the information that has been collected 
about you.   
 
9.    Questions or problems: 
 
If you have any questions about taking part in this study, you can meet with the 
investigators who are in charge of the study at this institution.  They are: Dr. Kathy 
Hodgkinson or Glenn Enright 
 
Dr. Kathy Hodgkinson, 777-6819   Glenn Enright, 699-8741 
 
Or you can talk to someone who is not involved with the study at all, but can advise 




Health Research Ethics Authority 




*Please return the completed signature page and surveys in the self-addressed 
postage paid envelope included in this package, and keep the rest of this document 
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Signature Page 
 
Study	  title:	  	  	  	  	  	  	  	  	  	  	  	  	  Understanding	  the	  psychosocial	  and	  economic	  effect	  of	  arrythmogenic	  right	  ventricular	  cardiomyopathy	  (ARVC)	  on	  families	  in	  Newfoundland	  and	  Labrador	  
                                                                                                                                    
Name(s) of principal investigators: Glenn Enright  
To be filled out and signed by the participant: 
Please check as appropriate: 
I have read the consent.      Yes { }     No { } 
I have had the opportunity to ask questions/to discuss this study Yes { }     No { } 
I have received satisfactory answers to all of my questions.  Yes { }     No { } 
I have received enough information about the study.   Yes { }     No { } 
I have spoken to Dr. Kathy Hodgkinson or Glenn Enright and she/he has 
answered my questions       Yes { }     No { } 
I understand that I am free to withdraw from the study  Yes { }     No { } 
• at any time 
• without having to give a reason 
• without affecting my health care  
I understand that it is my choice to be in the study and that I may not benefit.Yes }No { } 
I understand how my privacy is protected and my records kept confidential Yes { }     No 
{ } 
I agree that my data collected for this study be kept for 20 years. Yes { }     No { } 
I agree to take part in this study.        Yes { }     No { } 
I agree to be contacted for future research studies.   Yes { }     No { }                                                    
_______________________  _____________________    _______________    
Signature of participant    Name printed    Year Month Day 
 
__________________________________ ______________________     __________ 
Signature of person authorized as  Name printed      Year Month Day 
 
Substitute decision maker, if applicable____________________________________           
 
To be signed by the investigator or person obtaining consent 
 
I have explained this study to the best of my ability. I invited questions and gave answers. 
I believe that the participant fully understands what is involved in being in the study, any 
potential risks of the study and that he or she has freely chosen to be in the study. 
___________________________________  _____________________    
_______________    
Signature of investigator             Name printed      Year Month 
Day 
 
Telephone number:    _________________________ 
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Signature Page for Parent/Guardian  
Study	  title:	  	  	  	  	  	  	  	  	  	  	  Understanding	  the	  psychosocial	  and	  economic	  effect	  of	  arrythmogenic	  right	  ventricular	  cardiomyopathy	  (ARVC)	  on	  families	  in	  Newfoundland	  and	  Labrador	  
 
Name of principal investigator: Glenn Enright  
                                                                                                          
To be filled out and signed by the parent/guardian: 
Please check as 
appropriate: 
I have read the consent.Yes { }  No { }  
I have had the opportunity to ask questions/to discuss this study. Yes { }     No { } 
I have received satisfactory answers to all of my questions. Yes { }     No { } 
I have received enough information about the study. Yes { }     No { } 
I have spoken to, Dr. Kathy Hodgkinson or Glenn Enright and he/she has  
answered my questions Yes { }     No { } 
I understand that I am free to withdraw my child/ward from the study Yes { }     No { } 
• at any time 
• without having to give a reason 
• without affecting future care 
I understand that it is my choice for child/ward to be in the study and that he/she 
  may not benefit Yes { }   No { } 
I understand how my child/ward’s privacy is protected and records kept  
confidential          Yes { }  No { } 
I agree that my child’s/ward’s data collected in this study be kept for 20 years. Yes { }No 
{ } 
I agree to be contacted for future research studies.   Yes { }     No { }                                                    
I consent for my child/ward        to take part in 
this study.                                             Print Name   
        ________________________  _____________________    _______________    
Signature of parent/guardian   Name printed      Year Month Day 
 
_________________________  _____________________    _______________    
Signature of person conducting Name printed                  Year Month Day 
the consent discussion 
______________________________________________________________________ 
To be signed by the investigator: 
 have explained this study to the best of my ability. I invited questions and gave answers. 
I believe that the parent/guardian fully understands what is involved in being in the study, 
any potential risks of the study and that he or she has freely chosen for the child/ward to 
be in the study. 
 
__________________  _____________________    _______________    
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Signature of investigator   Name Printed      Year Month Day 
 
 
To be signed by the minor participant 
 
 
Study	  title:	  	  	  	  	  	  	  	  	  	  Understanding	  the	  psychosocial	  and	  economic	  effect	  of	  arrythmogenic	  right	  ventricular	  cardiomyopathy	  (ARVC)	  on	  families	  in	  Newfoundland	  and	  Labrador	  
                                                                                                                               
 
Name of principal investigator: Glenn Enright  
 
 
Assent of minor participant: 
 
I understand the purpose of this research  
I understand that it is my decision to take part in this study. I can stop taking part if 
I choose. 
I understand that taking part in this research may not help me.  
I agree that I will take part in this study  
             
Signature of minor participant           Year Month Day 




             
Name printed         Age    
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C2: Original Survey and Demographic Sheet 
	  
Economic	  Impact	  of	  ARVC	  Scale	  	  	   	  	  The	  Economic	  impact	  scale	  has	  8	  sections	  with	  a	  total	  of	  76	  questions.	  	  Each	  section	  has	  several	  statements	  that	  we	  would	  like	  you	  to	  rate	  from	  
1	  (Strongly	  disagree)	  to	  5	  (Strongly	  agree)	  or	  indicate	  Y	  (Yes)	  or	  N	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Section	  1:	  Education	  
The	  first	  section	  of	  this	  survey	  relates	  to	  education	  choices.	  Using	  the	  
scale	  given,	  you	  are	  asked	  to	  rate	  your	  agreement	  with	  each	  
statement	  as	  it	  reflects	  your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  N/A	  –	  Not	  applicable	  to	  me	  	  1.	  	  Identification	  of	  the	  gene	  change	  that	  causes	  ARVC	  in	  my	  family	  has	  influenced	  my	  education	  choices.	  2.	  My	  past	  education	  choices	  were	  influenced	  by	  my	  risk	  for	  ARVC.	  3.	  Knowing	  my	  risk	  for	  ARVC,	  I	  wish	  I	  had	  made	  different	  choices	  about	  my	  education.	  4.	  My	  decision	  to	  pursue	  education	  in	  the	  future	  is	  affected	  by	  my	  risk	  for	  ARVC.	  5.	  	  I	  encourage	  other	  family	  members	  to	  consider	  their	  risk	  for	  ARVC	  when	  making	  decisions	  about	  their	  education.	  6.	  Knowing	  their	  risk	  for	  ARVC	  has	  affected	  the	  education	  choices	  of	  other	  family	  members.	  	  7.	  Education	  choices	  are	  important	  to	  my	  family	  knowing	  the	  risk	  for	  ARVC.	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Section	  2:	  Career	  
The	  second	  section	  of	  this	  survey	  relates	  to	  career	  choices.	  Using	  the	  
scale	  given,	  you	  are	  asked	  to	  rate	  your	  agreement	  with	  each	  
statement	  as	  it	  reflects	  your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  N/A	  –	  Not	  applicable	  to	  me	  	  1.	  	  Identification	  of	  the	  gene	  change	  that	  causes	  ARVC	  in	  my	  family	  has	  influenced	  my	  career	  choices.	  2.	  My	  past	  career	  choices	  were	  influenced	  by	  my	  risk	  for	  ARVC.	  3.	  Knowing	  my	  risk	  for	  ARVC,	  I	  wish	  I	  had	  made	  different	  choices	  about	  my	  career.	  4.	  My	  decision	  to	  pursue	  certain	  careers	  in	  the	  future	  is	  affected	  by	  my	  risk	  for	  ARVC.	  5.	  	  I	  encourage	  other	  family	  members	  to	  consider	  their	  risk	  for	  ARVC	  when	  making	  decisions	  about	  their	  career.	  6.	  Knowing	  their	  risk	  for	  ARVC	  has	  affected	  the	  career	  choices	  of	  other	  family	  members.	  	  7.	  Medical	  benefits	  are	  an	  important	  factor	  when	  making	  career	  choices	  as	  a	  result	  of	  my	  family’s	  risk	  for	  ARVC.	  8.	  Career	  choices	  are	  important	  to	  my	  family	  knowing	  the	  risk	  for	  ARVC.	  	  	  
	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  N/A	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	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Section	  3:	  Indirect	  Costs	  
The	  third	  section	  of	  questions	  relates	  to	  personal	  indirect	  costs.	  
Using	  the	  scale	  given,	  you	  are	  asked	  to	  rate	  your	  agreement	  with	  
each	  statement	  as	  it	  reflects	  your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  Y	  –	  Yes	  N	  –	  No	  	  1.	  The	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  affected	  my	  employment.	  2.	  	  Knowing	  my	  risk	  for	  ARVC	  has	  caused	  me	  to	  work	  less	  than	  I	  did	  before	  finding	  out	  my	  risk.	  3.	  My	  work	  has	  been	  disrupted	  because	  of	  time	  off	  for	  medical	  appointments	  related	  to	  my	  risk	  for	  ARVC.	  4.	  My	  work	  has	  been	  disrupted	  because	  of	  time	  off	  for	  other	  family	  members’	  medical	  appointments	  related	  to	  their	  risk	  for	  ARVC.	  5.	  Knowing	  my	  risk	  for	  ARVC	  has	  caused	  me	  to	  work	  more	  than	  I	  did	  before	  finding	  out	  my	  risk.	  6.	  I	  have	  had	  to	  change	  the	  type	  of	  work	  that	  I	  do	  at	  my	  job	  because	  of	  my	  risk	  for	  ARVC.	  7.	  I	  have	  had	  to	  change	  careers/professions	  because	  of	  my	  risk	  for	  ARVC.	  8.	  My	  decision	  of	  when	  I	  retire	  has	  changed	  because	  of	  my	  risk	  for	  ARVC.	  9.	  My	  work	  has	  been	  disrupted	  because	  of	  time	  off	  to	  care	  for	  a	  family	  member,	  because	  of	  their	  risk	  for	  ARVC.	  10.	  I	  have	  had	  to	  work	  less	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  
	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	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11.	  I	  have	  had	  to	  work	  more	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  12.	  I	  have	  changed	  careers/professions	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  13.	  I	  am	  unable	  to	  work	  because	  of	  my	  risk	  for	  ARVC.	  	  14.	  I	  have	  had	  to	  go	  on	  short-­‐term	  disability	  because	  of	  my	  risk	  of	  ARVC.	  15.	  I	  have	  had	  to	  go	  on	  long-­‐term	  disability	  because	  of	  my	  risk	  of	  ARVC.	  16.	  I	  am	  unable	  to	  work	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  
	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Y	  	  	  	  	  	  	  	  N	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Y	  	  	  	  	  	  	  	  N	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Y	  	  	  	  	  	  	  	  N	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Y	  	  	  	  	  	  	  	  N	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   130 
Section	  4:	  Indirect	  Costs	  –	  Other	  Family	  Members	  
The	  fourth	  section	  of	  questions	  relates	  to	  indirect	  costs	  to	  other	  
family	  members.	  Using	  the	  scale	  given,	  you	  are	  asked	  to	  rate	  your	  
agreement	  with	  each	  statement	  as	  it	  reflects	  your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  Y	  –	  Yes	  N	  –	  No	  	  1.	  The	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  affected	  another	  family	  members’	  employment.	  2.	  	  Knowing	  my	  risk	  for	  ARVC	  has	  caused	  another	  family	  member	  to	  work	  less	  than	  they	  did	  before	  I	  found	  out	  my	  risk.	  3.	  Another	  family	  member’s	  work	  has	  been	  disrupted	  because	  of	  time	  off	  for	  medical	  appointments	  related	  to	  my	  risk	  for	  ARVC.	  4.	  Another	  family	  member	  has	  had	  to	  take	  time	  off	  work	  to	  care	  for	  me	  because	  of	  my	  risk	  for	  ARVC.	  5.	  Another	  family	  member	  has	  had	  to	  work	  
more	  because	  of	  my	  risk	  for	  ARVC.	  6.	  Another	  family	  member	  has	  had	  to	  change	  careers/professions	  because	  of	  my	  risk	  for	  ARVC.	  7.	  Another	  family	  member	  has	  changed	  their	  decision	  of	  when	  to	  retire	  because	  of	  my	  risk	  for	  ARVC.	  8.	  Another	  family	  member	  is	  unable	  to	  work	  because	  of	  my	  risk	  for	  ARVC.	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Section	  5:	  Income	  
The	  fifth	  set	  of	  questions	  relates	  to	  income.	  Using	  the	  scale	  given,	  you	  
are	  asked	  to	  rate	  your	  agreement	  with	  each	  statement	  as	  it	  reflects	  
your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  	  1.	  The	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  affected	  my	  income.	  2.	  My	  income	  has	  changed	  because	  of	  my	  risk	  for	  ARVC.	  3.	  My	  income	  is	  less	  because	  of	  my	  risk	  for	  ARVC.	  4.	  My	  income	  has	  changed	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  5.	  My	  income	  is	  less	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  6.	  The	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  affected	  another	  family	  member’s	  income.	  7.	  Another	  family	  member’s	  income	  has	  changed	  because	  of	  my	  risk	  for	  ARVC.	  8.	  Another	  family	  member’s	  income	  is	  less	  because	  of	  my	  risk	  for	  ARVC.	  9.	  Another	  family	  member’s	  income	  is	  more	  because	  of	  my	  risk	  for	  ARVC.	  10.	  The	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  affected	  my	  family’s	  total	  income.	  11.	  Changes	  to	  my	  family’s	  income	  because	  of	  the	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  been	  a	  financial	  burden.	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Section	  6:	  Direct	  Costs	  
The	  sixth	  section	  of	  questions	  relates	  to	  direct	  costs.	  Using	  the	  scale	  
given,	  you	  are	  asked	  to	  rate	  your	  agreement	  with	  each	  statement	  as	  
it	  reflects	  your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  	  1.	  	  The	  risk	  for	  ARVC	  in	  my	  family	  has	  been	  a	  financial	  burden.	  	  2.	  The	  need	  for	  regular	  monitoring	  for	  cardiac	  problems	  related	  to	  ARVC	  has	  been	  a	  financial	  burden	  on	  my	  family.	  3.	  My	  family	  has	  incurred	  costs	  because	  of	  the	  need	  for	  medications	  related	  to	  ARVC.	  4.	  The	  cost	  of	  medication	  related	  to	  ARVC	  has	  been	  a	  financial	  burden	  on	  our	  family.	  5.	  My	  family	  has	  incurred	  costs	  associated	  with	  travel	  for	  medical	  appointments	  (planned	  or	  unplanned)	  related	  to	  ARVC.	  6.	  My	  family	  has	  had	  to	  travel	  out	  of	  province	  for	  medical	  appointments/services	  related	  to	  ARVC.	  7.	  Costs	  associated	  with	  travel	  for	  medical	  appointments	  (planned	  or	  unplanned)	  related	  to	  ARVC	  have	  been	  a	  financial	  burden	  on	  my	  family.	  8.	  My	  family	  has	  incurred	  other	  costs	  associated	  with	  the	  ARVC	  gene.	  9.	  The	  other	  costs	  incurred	  by	  my	  family	  associated	  with	  the	  ARVC	  gene	  have	  been	  a	  financial	  burden.	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Section	  7:	  Insurance	  
The	  seventh	  section	  of	  questions	  relates	  to	  insurance.	  Using	  the	  scale	  
given,	  you	  are	  asked	  to	  rate	  how	  well	  each	  statement	  reflects	  your	  
situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  Y–	  Yes	  N–	  No	  N/A	  –	  Not	  Applicable	  to	  me	  	  1.	  The	  government’s	  Medicare	  plan	  covers	  costs	  associated	  with	  medical	  services	  related	  to	  my	  risk	  of	  ARVC.	  2.	  It	  is	  difficult	  for	  any	  member	  of	  my	  family	  (including	  myself)	  to	  buy	  medical	  insurance	  as	  a	  result	  of	  their	  risk	  for	  ARVC.	  3.	  My	  current	  medical	  insurance	  does	  not	  cover	  costs	  associated	  with	  the	  ARVC	  condition	  that	  are	  not	  already	  covered	  by	  the	  Government’s	  Medicare	  plan.	  4.	  I	  am	  concerned	  about	  the	  future	  ability	  of	  my	  family	  members	  to	  receive	  medical	  insurance	  as	  a	  result	  of	  their	  risk	  for	  ARVC.	  5.	  It	  is	  difficult	  for	  any	  member	  of	  my	  family	  (including	  myself)	  to	  purchase	  life	  insurance	  as	  a	  result	  of	  our	  risk	  for	  ARVC.	  6.	  Insurance	  is	  important	  to	  my	  family	  knowing	  the	  risk	  for	  ARVC.	  7.	  I	  have	  been	  denied	  medical	  insurance	  because	  of	  my	  risk	  for	  ARVC.	  8.	  I	  have	  paid	  a	  higher	  premium	  for	  medical	  insurance	  because	  of	  my	  risk	  for	  ARVC.	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  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  N/A	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Y	  	  	  	  	  	  	  	  	  	  	  	  N	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Y	  	  	  	  	  	  	  	  	  	  	  	  N	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Section	  8:	  Finances/Spending	  	  
The	  eighth	  section	  of	  questions	  relates	  to	  finances	  and	  spending.	  
Using	  the	  scale	  given,	  you	  are	  asked	  to	  rate	  how	  well	  each	  statement	  
reflects	  your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  	  1.	  I	  am	  concerned	  about	  the	  economic/financial	  future	  of	  my	  family	  as	  a	  result	  of	  my	  risk	  for	  ARVC.	  	  2.	  I	  am	  more	  aware	  of	  my	  spending	  habits	  as	  a	  result	  of	  my	  risk	  for	  ARVC.	  3.	  I	  have	  changed	  my	  spending	  habits	  because	  of	  my	  risk	  for	  ARVC.	  4.	  I	  do	  more	  financial	  planning	  (saving)	  because	  of	  my	  risk	  for	  ARVC.	  5.	  I	  am	  more	  aware	  of	  my	  spending	  habits	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  6.	  I	  am	  concerned	  about	  the	  economic/financial	  future	  of	  my	  family	  as	  a	  result	  of	  another	  family	  members’	  risk	  for	  ARVC.	  7.	  I	  have	  changed	  my	  spending	  habits	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  8.	  I	  do	  more	  financial	  planning	  (saving)	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  9.	  Finances	  are	  important	  to	  my	  family	  knowing	  the	  risk	  for	  ARVC.	  	  	  
	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	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Please	  tell	  us	  anything	  else	  you	  think	  is	  important	  for	  you	  or	  your	  
family’s	  economics	  in	  living	  with	  ARVC.	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Appendix D: Deceased Flowchart 










































Affected	  N=169	   Unaffected	  N=11	   Unknown	  N=34	  
Contacted	   Contacted	  
Yes	  N=3	   No	  N=166	   Yes	  N=1	   No	  N=10	  
Sent	  Survey	   Sent	  Survey	  
Yes	  N=0	   No	  N=3	   Yes	  N=0	   No	  N=1	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Appendix E: Ethics Approval and Amendments 
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Appendix F: Scale Validation Tables 
 
Table F1: Assignment of original survey items into hypothesized subscales. 
 Hypothesized  
Subscale 
 




   
Survey Item 
 
HC LSP CS FB IN Exc Binomial  
Edu1 X       HC1 
Edu2 X       HC2 
Edu3 X       HC3 
Edu4 X       HC4 
Edu5 X       HC5 
Edu6 X       HC6 
Edu7      X  N/A 
Car1 X       HC7 
Car2 X       HC8 
Car3 X       HC9 
Car4 X       HC10 
Car5 X       HC11 
Car6 X       HC12 
Car7      X  N/A 
Car8      X  N/A 
Ind1  X      LSP1 
Ind2  X      LSP2 
Ind3  X      LSP3 
Ind4  X      LSP4 
Ind5  X      LSP5 
Ind6  X      LSP6 
Ind7  X      LSP7 
Ind8  X      LSP8 
Ind9  X      LSP9 
Ind10  X      LSP10 
Ind11  X      LSP11 
Ind12  X      LSP12 
Ind13       X N/A 
Ind14       X N/A 
Ind15       X N/A 
Ind16       X N/A 
Indof1  X      LSP13 
Indof2  X      LSP14 
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 Hypothesized  
Subscale 
 




   
Survey Item 
 
HC LSP CS FB IN Exc Binomial  
Indof3  X      LSP15 
Indof4  X      LSP16 
Indof5  X      LSP17 
Indof6  X      LSP18 
Indof7  X      LSP19 
Indof8       X N/A 
Incm1  X      LSP20 
Incm2  X      LSP21 
Incm3  X      LSP22 
Incm4  X      LSP23 
Incm5  X      LSP24 
Incm6  X      LSP25 
Incm7  X      LSP26 
Incm8  X      LSP27 
Incm9  X      LSP28 
Incm10  X      LSP29 
Incm11    X    FB8 
Dir1    X    FB1 
Dir2    X    FB2 
Dir3   X     CS1 
Dir4    X    FB3 
Dir5   X     CS2 
Dir6      X  N/A 
Dir7    X    FB4 
Dir8   X     CS3 
Dir9    X    FB5 
Insur1      X  N/A 
Insur2     X   IN1 
Insur3     X   IN2 
Insur4     X   IN3 
Insur5     X   IN4 
Insur6      X  N/A 
Insur7       X N/A 
Insur8       X N/A 
Fin1    X    FB6 
Fin2   X     CS4 
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 Hypothesized  
Subscale 
 




   
Survey Item 
 
HC LSP CS FB IN Exc Binomial  
Fin3   X     CS5 
Fin4   X     CS6 
Fin5   X     CS7 
Fin6    X    FB7 
Fin7   X     CS8 
Fin8   X     CS9 
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Table F2: Survey item descriptives 
Item Mean SD Missing 
(%) 
Min Max Frequency of response values* 
      1 2 3 4 5 N/A§ 
            
Edu1 1.86 1.11 13.6 1 5 30 12 10 3 2 18 
Edu2 1.81 1.03 12.1 1 5 30 14 11 1 2  
Edu3 2.35 1.41 6.1 1 5 24 14 10 6 8  
Edu4 2.22 1.42 4.5 1 5 19 12 6 1 7  
Edu5 2.95 1.54 0.0 1 5 19 8 10 15 14  
Edu6 2.55 1.40 0.0 1 5 21 13 17 5 10  
Edu7 2.94 1.48 0.0 1 5 17 9 14 13 13  
Car1 2.20 1.30 10.6 1 5 22 19 8 4 6  
Car2 1.88 1.04 12.1 1 5 25 22 7 1 3  
Car3 2.50 1.46 9.1 1 5 19 19 4 9 9  
Car4 2.39 1.41 1.5 1 5 13 15 3 4 6 24 
Car5 3.03 1.42 1.5 1 5 14 10 13 16 12  
Car6 2.56 1.49 3.0 1 5 20 17 11 3 13  
Car7 3.50 1.56 0.0 1 5 14 3 11 12 26  
Car8 3.20 1.51 0.0 1 5 13 12 8 15 18  
Ind1 2.39 1.40 7.6 1 5 20 21 4 8 8  
Ind2 2.08 1.26 6.1 1 5 24 25 3 4 6  
Ind3 2.71 1.46 6.1 1 5 17 16 7 12 10  
Ind4 2.41 1.33 6.1 1 5 19 19 9 9 6  
Ind5 1.66 0.97 6.1 1 5 36 17 4 4 1  
Ind6 2.26 1.40 7.6 1 5 24 19 3 8 7  
Ind7 1.81 1.04 10.6 1 5 28 21 6 1 3  
Ind8 2.56 1.53 6.1 1 5 20 19 3 8 12  
Ind9 2.11 1.28 4.5 1 5 27 18 7 6 5  
Ind10 1.85 1.04 6.1 1 5 28 23 5 4 2  
Ind11 1.55 0.74 6.1 1 5 34 24 3 0 1  
Ind12 1.48 0.75 12.1 1 5 36 18 3 0 1  
Ind13 1.94 0.24 1.5 1 2 4 61     
Ind14 1.92 0.27 3.0 1 2 5 59     
Ind15 1.97 0.18 3.0 1 2 2 62     
Ind16 1.97 0.17 1.5 1 2 2 63     
Indof1 3.08 1.65 3.0 1 5 17 11 7 8 21  
Indof2 1.87 1.18 6.1 1 5 31 20 3 4 4  
Indof3 2.44 1.46 4.5 1 5 24 14 5 13 7  
Indof4 2.10 1.38 6.1 1 5 28 20 1 6 7  
Indof5 1.63 0.91 6.1 1 5 34 22 3 1 2  
Indof6 1.56 0.85 7.6 1 5 35 22 2 0 2  
Indof7 1.73 0.98 6.1 1 5 32 21 5 2 2  
Indof8 2.00 0.00 3.0 2 2 0 64     
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Item Mean SD Missing 
(%) 
Min Max Frequency of response values* 
      1 2 3 4 5 N/A§ 
Incm1 2.19 1.43 4.5 1 5 27 20 2 5 9  
Incm2 2.06 1.33 6.1 1 5 27 22 2 4 7  
Incm3 2.14 1.40 4.5 1 5 27 21 3 3 9  
Incm4 1.67 1.06 4.5 1 5 37 19 1 3 3  
Incm5 1.73 1.12 4.5 1 5 36 18 3 2 4  
Incm6 2.44 1.49 4.5 1 5 24 14 8 7 10  
Incm7 1.66 0.97 4.5 1 5 36 18 4 4 1  
Incm8 1.59 0.87 4.5 1 5 36 21 4 0 2  
Incm9 1.58 0.87 6.1 1 5 36 21 2 1 2  
Incm10 2.14 1.38 4.5 1 5 29 16 4 8 6  
Incm11 2.02 1.28 4.5 1 5 29 19 6 3 6  
Dir1 1.98 1.24 3.0 1 5 29 21 6 2 6  
Dir2 2.06 1.14 3.0 1 5 24 24 7 6 3  
Dir3 2.41 1.46 4.5 1 5 24 15 6 10 8  
Dir4 2.08 1.20 3.0 1 5 26 19 12 2 5  
Dir5 3.03 1.52 3.0 1 5 16 11 5 19 13  
Dir6 2.42 1.52 3.0 1 5 25 17 2 10 10  
Dir7 2.64 1.40 3.0 1 5 17 18 9 11 9  
Dir8 2.48 1.43 3.0 1 5 22 16 6 13 7  
Dir9 2.31 1.39 3.0 1 5 24 18 8 6 8  
Insur1 3.61 1.16 7.6 1 5 6 4 9 31 11 17 
Insur2 3.63 1.37 4.5 1 5 4 7 9 8 18  
Insur3 2.70 1.25 4.5 1 5 7 16 9 7 5 19 
Insur4 3.69 1.31 7.6 1 5 7 3 13 17 21  
Insur5 3.94 1.27 4.5 1 5 4 2 12 8 25 12 
Insur6 4.11 1.18 6.1 1 5 3 4 9 13 33  
Insur7 1.73 0.45 4.5 1 2 17 46     
Insur8 1.82 0.39 6.1 1 2 11 51     
Fin1 2.78 1.48 4.5 1 5 17 14 9 12 11  
Fin2 2.52 1.37 4.5 1 5 20 14 11 12 6  
Fin3 2.43 1.38 4.5 1 5 21 17 9 9 7  
Fin4 2.44 1.38 4.5 1 5 23 13 7 16 4  
Fin5 2.11 1.27 4.5 1 5 27 17 9 5 5  
Fin6 2.38 1.44 4.5 1 5 24 15 9 6 9  
Fin7 2.10 1.20 4.5 1 5 26 17 12 4 4  
Fin8 2.17 1.31 6.1 1 5 26 16 8 7 5  
Fin9 3.33 1.46 3.0 1 5 15 2 7 27 13  
* Response values indicate level of agreement, 1 (strongly disagree) through 5 (strongly agree) for likert 
scoring items, and, 1 (yes) to 2 (no) for binomial items. 
§ Only items that were identified as possibly not applicable to some participants included a N/A response 
option 
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Scale = HC (Human Capital)           
HC1 1.86 1.11 0.66 0.40 0.45 0.39 0.30 
HC2 1.81 1.03 0.78 0.37 0.31 0.29 0.22 
HC3 2.35 1.42 0.71 0.34 0.34 0.32 0.36 
HC4 2.22 1.43 0.81 0.38 0.42 0.46 0.30 
HC5 2.95 1.54 0.83 0.52 0.49 0.48 0.42 
HC6 2.55 1.41 0.78 0.46 0.43 0.36 0.47 
HC7 2.20 1.30 0.84 0.55 0.49 0.57 0.46 
HC8 1.88 1.04 0.68 0.43 0.31 0.41 0.36 
HC9 2.50 1.46 0.78 0.44 0.37 0.40 0.46 
HC10 2.39 1.41 0.83 0.52 0.57 0.60 0.42 
HC11 3.03 1.42 0.79 0.52 0.44 0.44 0.40 
HC12 2.56 1.49 0.76 0.44 0.38 0.34 0.43 
                
Scale = LSP (Labour Supply and Productivity)        
LSP1 2.39 1.41 0.59 0.66 0.44 0.51 0.36 
LSP2 2.08 1.26 0.63 0.67 0.55 0.56 0.41 
LSP3 2.71 1.46 0.50 0.54 0.34 0.37 0.44 
LSP4 2.42 1.33 0.41 0.58 0.49 0.49 0.33 
LSP5 1.66 0.97 0.18 0.42 0.38 0.40 0.01 
LSP6 2.26 1.40 0.64 0.60 0.49 0.48 0.47 
LSP7 1.81 1.04 0.57 0.53 0.40 0.43 0.29 
LSP8 2.56 1.53 0.66 0.69 0.49 0.51 0.46 
LSP9 2.11 1.28 0.41 0.65 0.51 0.55 0.30 
LSP10 1.85 1.04 0.32 0.64 0.50 0.52 0.22 
LSP11 1.55 0.74 0.22 0.49 0.30 0.31 0.14 
LSP12 1.48 0.75 0.18 0.41 0.25 0.24 0.11 
LSP13 3.08 1.65 0.24 0.52 0.31 0.36 0.41 
LSP14 1.87 1.18 0.26 0.63 0.39 0.40 0.24 
LSP15 2.44 1.46 0.31 0.57 0.33 0.32 0.36 
LSP16 2.10 1.38 0.26 0.62 0.31 0.34 0.43 
LSP17 1.63 0.91 0.10 0.70 0.24 0.31 0.18 
LSP18 1.56 0.85 0.11 0.63 0.18 0.25 0.14 
LSP19 1.73 0.98 0.22 0.74 0.27 0.34 0.24 
LSP20 2.19 1.44 0.45 0.73 0.44 0.46 0.30 



















LSP21 2.06 1.33 0.48 0.77 0.51 0.56 0.35 
LSP22 2.14 1.40 0.51 0.77 0.49 0.52 0.39 
LSP23 1.67 1.06 0.21 0.67 0.45 0.51 0.07 
LSP24 1.73 1.12 0.22 0.66 0.51 0.60 0.10 
LSP25 2.44 1.49 0.25 0.47 0.26 0.32 0.11 
LSP26 1.67 0.97 0.29 0.71 0.45 0.54 0.18 
LSP27 1.59 0.87 0.35 0.67 0.40 0.51 0.15 
LSP28 1.58 0.90 0.25 0.65 0.36 0.42 0.15 
LSP29 2.14 1.38 0.49 0.77 0.51 0.55 0.24 
                
Scale =CS (Consumption and Savings)          
CS1 2.41 1.46 0.32 0.54 0.73 0.68 0.30 
CS2 3.03 1.52 0.16 0.24 0.60 0.57 0.34 
CS3 2.48 1.43 0.28 0.42 0.65 0.72 0.27 
CS4 2.52 1.37 0.61 0.58 0.85 0.74 0.37 
CS5 2.43 1.38 0.61 0.60 0.81 0.73 0.35 
CS6 2.44 1.38 0.59 0.59 0.72 0.58 0.37 
CS7 2.11 1.27 0.41 0.49 0.81 0.73 0.14 
CS8 2.10 1.20 0.36 0.43 0.82 0.75 0.14 
CS8 2.18 1.31 0.39 0.44 0.76 0.69 0.22 
                
Scale  = FB (Financial Burden)          
FB1 1.98 1.24 0.53 0.74 0.76 0.86 0.25 
FB2 2.06 1.14 0.30 0.49 0.71 0.82 0.15 
FB3 2.08 1.20 0.42 0.63 0.73 0.76 0.30 
FB4 2.64 1.41 0.08 0.30 0.64 0.70 0.25 
FB5 2.31 1.39 0.23 0.45 0.68 0.78 0.17 
FB6 2.78 1.48 0.72 0.61 0.77 0.77 0.47 
FB7 2.38 1.44 0.48 0.41 0.72 0.72 0.25 
FB8 2.02 1.28 0.50 0.81 0.75 0.85 0.27 
                
Scale = IN (Insurance)             
IN1 3.63 1.37 0.48 0.48 0.36 0.32 0.85 
IN2 2.70 1.25 0.00 -0.06 0.01 -0.03 0.56 
IN3 3.69 1.31 0.57 0.56 0.44 0.43 0.80 
IN4 3.94 1.27 0.48 0.44 0.41 0.45 0.81 
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Table F4: Item Discriminant Validity Tests 
Item Name HC LSP CS FB IN 
 
          
Scale = HC (Human Capital) 
  
HC1 ** 2.00 1.00 2.00 2.00 
HC2 ** 2.00 2.00 2.00 2.00 
HC3 ** 2.00 2.00 2.00 2.00 
HC4 ** 2.00 2.00 2.00 2.00 
HC5 ** 2.00 2.00 2.00 2.00 
HC6 ** 2.00 2.00 2.00 2.00 
HC7 ** 2.00 2.00 2.00 2.00 
HC8 ** 1.00 2.00 2.00 2.00 
HC9 ** 2.00 2.00 2.00 2.00 
HC10 ** 2.00 1.00 1.00 2.00 
HC11 ** 2.00 2.00 2.00 2.00 
HC12 ** 2.00 2.00 2.00 2.00 
            
Scale = LSP (Labour Supply and Productivity) 
  
LSP1 1.00 ** 1.00 1.00 2.00 
LSP2 1.00 ** 1.00 1.00 2.00 
LSP3 1.00 ** 1.00 1.00 1.00 
LSP4 1.00 ** 1.00 1.00 2.00 
LSP5 1.00 ** 1.00 1.00 2.00 
LSP6 -1.00 ** 1.00 1.00 1.00 
LSP7 -1.00 ** 1.00 1.00 1.00 
LSP8 1.00 ** 1.00 1.00 1.00 
LSP9 1.00 ** 1.00 1.00 2.00 
LSP10 2.00 ** 1.00 1.00 2.00 
LSP11 2.00 ** 1.00 1.00 2.00 
LSP12 1.00 ** 1.00 1.00 2.00 
LSP13 2.00 ** 1.00 1.00 1.00 
LSP14 2.00 ** 1.00 1.00 2.00 
LSP15 2.00 ** 1.00 2.00 1.00 
LSP16 2.00 ** 2.00 2.00 1.00 
LSP17 2.00 ** 2.00 2.00 2.00 
LSP18 2.00 ** 2.00 2.00 2.00 
LSP19 2.00 ** 2.00 2.00 2.00 
LSP20 2.00 ** 2.00 2.00 2.00 
LSP21 2.00 ** 2.00 1.00 2.00 
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Item Name HC LSP CS FB IN 
LSP22 2.00 ** 2.00 2.00 2.00 
LSP23 2.00 ** 1.00 1.00 2.00 
LSP24 2.00 ** 1.00 1.00 2.00 
LSP25 1.00 ** 1.00 1.00 2.00 
LSP26 2.00 ** 2.00 1.00 2.00 
LSP27 2.00 ** 2.00 1.00 2.00 
LSP28 2.00 ** 2.00 1.00 2.00 
LSP29 2.00 ** 2.00 1.00 2.00 
            
Scale =CS (Consumption and Savings)  
 
CS1 2.00 1.00 ** 1.00 2.00 
CS2 2.00 2.00 ** 1.00 2.00 
CS3 2.00 1.00 ** -1.00 2.00 
CS4 1.00 2.00 ** 1.00 2.00 
CS5 1.00 1.00 ** 1.00 2.00 
CS6 1.00 1.00 ** 1.00 2.00 
CS7 2.00 2.00 ** 1.00 2.00 
CS8 2.00 2.00 ** 1.00 2.00 
CS8 2.00 2.00 ** 1.00 2.00 
            
Scale  = FB (Financial Burden) 
FB1 2.00 1.00 1.00 ** 2.00 
FB2 2.00 2.00 1.00 ** 2.00 
FB3 2.00 1.00 1.00 ** 2.00 
FB4 2.00 2.00 1.00 ** 2.00 
FB5 2.00 2.00 1.00 ** 2.00 
FB6 1.00 1.00 1.00 ** 2.00 
FB7 1.00 2.00 1.00 ** 2.00 
FB8 2.00 1.00 1.00 ** 2.00 
            
Scale = IN (Insurance) 
  
IN1 2.00 2.00 2.00 2.00 ** 
IN2 2.00 2.00 2.00 2.00 ** 
IN3 1.00 1.00 2.00 2.00 ** 
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Appendix G: SPSS® Normality Probability Plot of Regression Standardized 








Figure G2: SPSS® Scatterplot for HC scale regression analysis 
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Figure G4: SPSS® Scatterplot for LSP scale regression analysis 
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Figure G6: SPSS® Scatterplot for CS scale regression analysis 
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Figure G7: SPSS® Normal probability plot for FB scale regression analysis. 
 
 
Figure G8: SPSS® Scatterplot for FB scale regression analysis 
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Figure G10: SPSS® Scatterplot for IN scale regression analysis 
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Appendix H: Validated PEB Scale Survey 
 
 
Perceived	  Economic	  Burden	  (PEB)	  of	  ARVC	  Scale	  	  	   	  	  The	  validated	  Perceived	  Economic	  Burden	  scale	  has	  5	  sections	  with	  a	  total	  of	  62	  questions.	  	  Each	  section	  has	  several	  statements	  that	  we	  would	  like	  you	  to	  rate	  from	  1	  (Strongly	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Section	  1:	  Human	  Capital	  Attainment	  
The	  first	  section	  of	  this	  survey	  relates	  to	  education	  and	  career	  choices.	  Using	  the	  
scale	  given,	  you	  are	  asked	  to	  rate	  your	  agreement	  with	  each	  statement	  as	  it	  
reflects	  your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  N/A	  –	  Not	  applicable	  to	  me	  	  1.	  	  Identification	  of	  the	  gene	  change	  that	  causes	  ARVC	  in	  my	  family	  has	  influenced	  my	  education	  choices.	  2.	  My	  past	  education	  choices	  were	  influenced	  by	  my	  risk	  for	  ARVC.	  3.	  Knowing	  my	  risk	  for	  ARVC,	  I	  wish	  I	  had	  made	  different	  choices	  about	  my	  education.	  4.	  My	  decision	  to	  pursue	  education	  in	  the	  future	  is	  affected	  by	  my	  risk	  for	  ARVC.	  5.	  	  I	  encourage	  other	  family	  members	  to	  consider	  their	  risk	  for	  ARVC	  when	  making	  decisions	  about	  their	  education.	  6.	  Knowing	  their	  risk	  for	  ARVC	  has	  affected	  the	  education	  choices	  of	  other	  family	  members.	  	  7.	  	  Identification	  of	  the	  gene	  change	  that	  causes	  ARVC	  in	  my	  family	  has	  influenced	  my	  career	  choices.	  8.	  My	  past	  career	  choices	  were	  influenced	  by	  my	  risk	  for	  ARVC.	  9.	  Knowing	  my	  risk	  for	  ARVC,	  I	  wish	  I	  had	  made	  different	  choices	  about	  my	  career.	  10.	  My	  decision	  to	  pursue	  certain	  careers	  in	  the	  future	  is	  affected	  by	  my	  risk	  for	  ARVC.	  11.	  	  I	  encourage	  other	  family	  members	  to	  consider	  their	  risk	  for	  ARVC	  when	  making	  decisions	  about	  their	  career.	  12.	  Knowing	  their	  risk	  for	  ARVC	  has	  affected	  the	  career	  choices	  of	  other	  family	  members.	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Section	  2:	  Labour	  Supply	  And	  Productivity	  
The	  second	  section	  of	  this	  survey	  relates	  to	  your/your	  family	  experiences	  with	  
work.	  Using	  the	  scale	  given,	  you	  are	  asked	  to	  rate	  your	  agreement	  with	  each	  
statement	  as	  it	  reflects	  your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  N/A	  –	  Not	  applicable	  to	  me	  	  	  1.	  The	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  affected	  my	  employment.	  2.	  	  Knowing	  my	  risk	  for	  ARVC	  has	  caused	  me	  to	  work	  
less	  than	  I	  did	  before	  finding	  out	  my	  risk.	  3.	  My	  work	  has	  been	  disrupted	  because	  of	  time	  off	  for	  medical	  appointments	  related	  to	  my	  risk	  for	  ARVC.	  4.	  My	  work	  has	  been	  disrupted	  because	  of	  time	  off	  for	  other	  family	  members’	  medical	  appointments	  related	  to	  their	  risk	  for	  ARVC.	  5.	  Knowing	  my	  risk	  for	  ARVC	  has	  caused	  me	  to	  work	  
more	  than	  I	  did	  before	  finding	  out	  my	  risk.	  6.	  I	  have	  had	  to	  change	  the	  type	  of	  work	  that	  I	  do	  at	  my	  job	  because	  of	  my	  risk	  for	  ARVC.	  7.	  I	  have	  had	  to	  change	  careers/professions	  because	  of	  my	  risk	  for	  ARVC.	  8.	  My	  decision	  of	  when	  I	  retire	  has	  changed	  because	  of	  my	  risk	  for	  ARVC.	  9.	  My	  work	  has	  been	  disrupted	  because	  of	  time	  off	  to	  care	  for	  a	  family	  member,	  because	  of	  their	  risk	  for	  ARVC.	  10.	  I	  have	  had	  to	  work	  less	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  11.	  I	  have	  had	  to	  work	  more	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  12.	  I	  have	  changed	  careers/professions	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  13.	  The	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  affected	  another	  family	  members’	  employment.	  
	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  
	   163 
14.	  	  Knowing	  my	  risk	  for	  ARVC	  has	  caused	  another	  family	  member	  to	  work	  less	  than	  they	  did	  before	  I	  found	  out	  my	  risk.	  15.	  Another	  family	  member’s	  work	  has	  been	  disrupted	  because	  of	  time	  off	  for	  medical	  appointments	  related	  to	  my	  risk	  for	  ARVC.	  16.	  Another	  family	  member	  has	  had	  to	  take	  time	  off	  work	  to	  care	  for	  me	  because	  of	  my	  risk	  for	  ARVC.	  17.	  Another	  family	  member	  has	  had	  to	  work	  more	  because	  of	  my	  risk	  for	  ARVC.	  18.	  Another	  family	  member	  has	  had	  to	  change	  careers/professions	  because	  of	  my	  risk	  for	  ARVC.	  19.	  Another	  family	  member	  has	  changed	  their	  decision	  of	  when	  to	  retire	  because	  of	  my	  risk	  for	  ARVC.	  20.	  The	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  affected	  my	  income.	  21.	  My	  income	  has	  changed	  because	  of	  my	  risk	  for	  ARVC.	  22.	  My	  income	  is	  less	  because	  of	  my	  risk	  for	  ARVC.	  23.	  My	  income	  has	  changed	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  24.	  My	  income	  is	  less	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  25.	  The	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  affected	  another	  family	  member’s	  income.	  26.	  Another	  family	  member’s	  income	  has	  changed	  because	  of	  my	  risk	  for	  ARVC.	  27.	  Another	  family	  member’s	  income	  is	  less	  because	  of	  my	  risk	  for	  ARVC.	  28.	  Another	  family	  member’s	  income	  is	  more	  because	  of	  my	  risk	  for	  ARVC.	  29.	  The	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  affected	  my	  family’s	  total	  income.	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Section	  3:	  Consumption	  and	  Savings	  
The	  third	  section	  of	  questions	  relates	  to	  personal	  direct	  costs	  and	  financial	  
decisions.	  Using	  the	  scale	  given,	  you	  are	  asked	  to	  rate	  your	  agreement	  with	  each	  
statement	  as	  it	  reflects	  your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  Y	  –	  Yes	  N	  –	  No	  	  1.	  My	  family	  has	  incurred	  costs	  because	  of	  the	  need	  for	  medications	  related	  to	  ARVC	  	  2.	  My	  family	  has	  incurred	  costs	  associated	  with	  travel	  for	  medical	  appointments	  (planned	  or	  unplanned)	  related	  to	  ARVC.	  3.	  My	  family	  has	  incurred	  other	  costs	  associated	  with	  the	  ARVC	  gene.	  4.	  I	  am	  more	  aware	  of	  my	  spending	  habits	  as	  a	  result	  of	  my	  risk	  for	  ARVC.	  5.	  I	  have	  changed	  my	  spending	  habits	  because	  of	  my	  risk	  for	  ARVC.	  6.	  I	  do	  more	  financial	  planning	  (saving)	  because	  of	  my	  risk	  for	  ARVC.	  7.	  I	  am	  more	  aware	  of	  my	  spending	  habits	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  8.	  I	  have	  changed	  my	  spending	  habits	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	  9.	  I	  do	  more	  financial	  planning	  (saving)	  because	  of	  another	  family	  member’s	  risk	  for	  ARVC.	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Section	  4:	  Financial	  Burden	  
The	  fourth	  section	  of	  questions	  relates	  to	  financial	  burden.	  Using	  the	  scale	  given,	  
you	  are	  asked	  to	  rate	  your	  agreement	  with	  each	  statement	  as	  it	  reflects	  your	  
situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  Y	  –	  Yes	  N	  –	  No	  	  1.	  	  The	  risk	  for	  ARVC	  in	  my	  family	  has	  been	  a	  financial	  burden.	  	  2.	  The	  need	  for	  regular	  monitoring	  for	  cardiac	  problems	  related	  to	  ARVC	  has	  been	  a	  financial	  burden	  on	  my	  family.	  3.	  The	  cost	  of	  medication	  related	  to	  ARVC	  has	  been	  a	  financial	  burden	  on	  our	  family.	  4.	  Costs	  associated	  with	  travel	  for	  medical	  appointments	  (planned	  or	  unplanned)	  related	  to	  ARVC	  have	  been	  a	  financial	  burden	  on	  my	  family.	  5.	  The	  other	  costs	  incurred	  by	  my	  family	  associated	  with	  the	  ARVC	  gene	  have	  been	  a	  financial	  burden.	  6.	  I	  am	  concerned	  about	  the	  economic/financial	  future	  of	  my	  family	  as	  a	  result	  of	  my	  risk	  for	  ARVC.	  7.	  My	  family	  has	  had	  to	  travel	  out	  of	  province	  for	  medical	  appointments/services	  related	  to	  ARVC.	  8.	  Changes	  to	  my	  family’s	  income	  because	  of	  the	  presence	  of	  the	  gene	  that	  causes	  ARVC	  in	  my	  family	  has	  been	  a	  financial	  burden.	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Section	  5:	  Insurance	  
The	  seventh	  section	  of	  questions	  relates	  to	  insurance.	  Using	  the	  scale	  given,	  you	  
are	  asked	  to	  rate	  how	  well	  each	  statement	  reflects	  your	  situation.	  	  1	  –	  Strongly	  disagree	  2	  –	  Disagree	  3	  –	  Neither	  agree	  nor	  disagree	  4	  –	  Agree	  5	  –	  Strongly	  agree	  Y–	  Yes	  N–	  No	  N/A	  –	  Not	  Applicable	  to	  me	  	  1.	  It	  is	  difficult	  for	  any	  member	  of	  my	  family	  (including	  myself)	  to	  buy	  medical	  insurance	  as	  a	  result	  of	  their	  risk	  for	  ARVC.	  2.	  My	  current	  medical	  insurance	  does	  not	  cover	  costs	  associated	  with	  the	  ARVC	  condition	  that	  are	  not	  already	  covered	  by	  the	  Government’s	  Medicare	  plan.	  3.	  I	  am	  concerned	  about	  the	  future	  ability	  of	  my	  family	  members	  to	  receive	  medical	  insurance	  as	  a	  result	  of	  their	  risk	  for	  ARVC.	  4.	  It	  is	  difficult	  for	  any	  member	  of	  my	  family	  (including	  myself)	  to	  purchase	  life	  insurance	  as	  a	  result	  of	  our	  risk	  for	  ARVC.	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